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Pseudomonas aeruginosa is a clinically important, opportunistic bacterial pathogen that can 
cause a wide range of severe infections. The bacterium is inherently resistant to many 
antibiotics and chronic infections are very difficult to treat.  Patients with the genetic disease 
cystic fibrosis (CF) often have recurrent P. aeruginosa pulmonary infections resulting in 
robust inflammatory responses that lead to tissue destruction. Despite a hostile hyper-
inflammatory environment and vigorous neutrophilic responses, P. aeruginosa can persist in 
the CF lung and eventually become the dominant bacterium in the airways.  
We demonstrate that P. aeruginosa manipulates host lipid signaling and inflammatory 
response in the CF airway by secreting Cif, a virulence factor with epoxide hydrolase activity. 
Cif reduced the transcellular production of 15-epi lipoxin A4 (15-epi LXA4), a pro-resolving 
lipid mediator whose endogenous production is critical in limiting tissue inflammation. In the 
airway, neutrophil 15-epi LXA4 production is stimulated by the epithelial-derived eicosanoid 
14,15-epoxyeicosatrienoic acid (14,15-EET). Cif sabotaged the production of 15-epi LXA4 by 
rapidly hydrolyzing 14,15-EET into its cognate diol, eliminating neutrophil generation of 15-
epi LXA4. Cif mediated inhibition of 15-epi LXA4 eliminated the pro-resolving signal that 
potently suppresses IL-8-driven neutrophil trans-epithelial migration in vitro. Moreover, our 
retrospective analyses of CF patient samples supported the translational relevance of these 
preclinical findings. Elevated levels of Cif in bronchoalveolar lavage fluid correlated with 
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lower levels of 15-epi LXA4, increased IL-8 concentrations and impaired lung function. These 
findings provide structural, biochemical and immunological evidence that the P. aeruginosa 
epoxide hydrolase Cif disrupts resolution pathways during bacterial lung infections in the CF 
airway. This study and the recent identification of Cif homologs in Acinetobacter and 
Burkholderia species suggest that bacterial epoxide hydrolases represent a novel virulence 
strategy shared by multiple respiratory pathogens.   
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1.0 PULMONARY INFECTION IN CYSTIC FIBROSIS 
  1.1 CYSTIC FIBROSIS: THE VICIOUS CYCLE 
Cystic fibrosis (CF) is a life-threatening genetic disease caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR). There is no cure and it is estimated 
that almost 70,000 individuals worldwide and 30,000 in the United States suffer from CF. 
Although patients experience serious gastrointestinal, endocrine and fertility disorders, the 
majority of deaths associated with the disease are due to respiratory failure [3, 4]. Progressive 
lung deterioration is often the most challenging in the management of CF and is the major 
determinant of life span and quality of life in affected individuals. The loss of CFTR function 
results in poor innate epithelial defense and dysfunctional neutrophil responses, which are 
unable to eliminate bacterial pathogens from the CF airway. Substantial clinical data 
demonstrate Pseudomonas aeruginosa respiratory infections in the CF lung correlate with 
symptomatic lung disease, which is marked by excessive airway inflammation [4-6]. 
Persistent bacterial infections in the CF respiratory tract promote a perpetuating cycle of 
vigorous inflammation, resulting in extensive damage to tissue and eventually respiratory 
failure. 
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1.1.1  CFTR activity and airway epithelial host defense in the cystic fibrosis lung 
The removal of foreign particles and pathogens from the lungs depend on the coordinated 
directional movement of the mucus secretions by ciliated cells that line the airways, termed 
mucociliary clearance [7].  In individuals with CF, mutations in CFTR cause thick mucus 
secretions to accumulate in the lung.  CFTR is an anion channel that transports Cl− and 
HCO3− ions across epithelial cell surfaces and whose function is essential for maintaining 
airway surface liquid (ASL), a critical component of innate host defense [8, 9].  ASL is 
comprised of two layered secretions, aqueous perciliary fluid coated by mucus secretions 
[10]. The periciliary fluid is directly above and in contact with airway epithelial cells (AEC), 
affording space for ciliary beat by distancing the mucus from the cell surface. Mucus 
secretions trap inhaled debris and microorganisms, which is then removed from the lung via 
mucociliary clearance. In CF, the loss of CFTR function results in sodium ion and water 
hyper-absorption by epithelial cells, resulting in the dehydrated periciliary fluid and dense 
mucous secretions [10]. 
In addition to sequestering and removing debris from the lung, ASL also contains 
numerous antimicrobial peptides, proteins, and lipids, which are important for innate mucosal 
defense [11]. The reduction of CFTR mediated HCO3− secretion by CF airway epithelia 
lowers the acidity of ASL, which has a negative impact on mucosal innate immunity [12-
14].  Studies using CF pig models and primary CF epithelial cells demonstrate that the acidic 
environment in the CF lung reduces the activity of antimicrobial peptides and innate host 
defense [9, 14]. Acidic pH can reduce epithelial secretion of beta-defensins [15] and inhibit 
the functional activity of LL-37 [16]. Furthermore, HCO3− has also been shown to have pH 
independent effects on antimicrobial peptide function and is a critical ionic factor that can 
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directly enhance antimicrobial peptide activity [17]. As antimicrobial peptides in the ASL 
have synergistic interactions, a reduction of HCO3− secretion and pH in the CF lung may 
disrupt these cooperative relationships [18, 19].  
Defective HCO3−secretion also disrupts rheological properties of mucins and is 
associated with abnormal mucus viscosity in CF [20]. The accumulation of dense and 
adhesive mucous, a reduction in normal mucociliary clearance and reduced antimicrobial 
peptide function produces conditions ideal for supporting robust bacterial growth in the CF 
airway. Despite repetitive antibiotic therapy, pulmonary bacterial infections still remain the 
primary cause of morbidity and mortality in CF patients. Thus, mutations in CFTR result in 
defective mucociliary clearance and poor innate antimicrobial activity in the CF airway, two 
very important features for normal lung function.  
1.1.2 Dysfunctional neutrophil responses 
Progressive bronchiectasis in CF is largely the result of persistent neutrophil accumulation 
and release of harmful proteases [21]. Neutrophil are often the first immune cells recruited to 
inflamed tissues and provide non-specific host defense through phagocytosis and the 
secretion of antimicrobial peptides and proteases [22].  However, in CF unrelenting 
neutrophil accumulation in the lung is ineffective at controlling pulmonary infections [21]. 
Although early work suggested that CFTR was not expressed on neutrophils [23], 
recent studies demonstrate not only is the anion channel important in neutrophil function, but 
loss of CFTR results in dysfunctional activity  [24, 25]. Absent or defective CFTR results in 
abnormal phagolysosome chlorination of engulfed pathogens thus impairing neutrophil 
microbial killing activity [26-28]. One recent study demonstrated neutrophils from CF patient 
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sputum displayed functional exhaustion and reduced respiratory burst capacity compared to 
matched peripheral blood neutrophils [29]. CF neutrophils also have reduced surface 
expression of CD14, CD16 and CXCR1, which has been linked to poor phagocytic capacity 
[30, 31]. Interestingly, CF patients do not have difficulty containing bacterial infections 
outside of the lung and it remains unclear why abnormal neutrophil function is important for 
controlling infection in the airway, but not in other organs. 
Many chemoattractants contribute to the neutrophil accumulation in the CF airway. 
The CF lung contains massive amounts of IL-8, LTB4, C5a, IL-17 and bacterial products 
such as N-formyl-methionyl-leucyl-phenylalanine (fMLP) [32-37]. The steep gradient of 
these chemoattractants in the lung, especially IL-8 is a hallmark of CF lung disease 
progression. However the relative contribution of these inflammatory mediators varies by 
individual patient [21]. The absence or dysfunction of CFTR does not appear to enhance the 
migration of CF neutrophils across epithelial cells [38]. However, AECs deficient in CFTR 
express elevated levels of adhesion molecules [39], which may increase neutrophil 
attachment to enhance transepithelial migration.  Interestingly, studies have shown that 
purified blood neutrophils from CF patients migrate significantly faster through a 
Transwell filter compared to non-CF cells in response to IL-8 [40]. This suggests that CF 
neutrophils are already primed for activation in the periphery, most likely by the elevated 
production of soluble inflammatory molecules in CF patients. 
The accumulation of dysfunctional neutrophils results in a large amount of proteases 
released into the airway, not only causing tissue damage, but also inactivating many host 
defense mechanisms. The concentration of proteases released in the CF airway environment 
also overwhelms host systems, particularly alpha-1-protease inhibitor and secretory 
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leukocyte protease inhibitor [41] which neutralize the toxic effects of neutrophil proteases. 
Cathepsin G, a protease released from primary neutrophil granules is found in large 
quantities in the CF lung and in a low pH environments can cleave and inactivate lactoferrin 
[42] and surfactant protein A [43] reducing their antimicrobial activity. The release of the 
neutrophil protease elastase has several deleterious effects and its concentrations measured in 
CF sputum correlate with pulmonary function [44, 45]. Elastase causes structural damage to 
the epithelial tight junctions promoting detachment [46] and also activates the apical 
epithelial sodium channel (ENaC) thereby increasing sodium hyperabsorption and further 
decreasing airway surface liquid height [47]. The abundance of elastase in CF lungs cleaves 
and impairs CXCR1 and complement receptors, which hinders bacterial phagocytosis and 
killing [46, 47]. Neutrophil elastase degrades macrophage phosphatidylserine receptors 
efferocytosis and inhibits normal resolution of inflammation [48]. Lastly, neutrophils also 
release large amounts of matrix metalloproteases into the CF airway [49], which digest the 
extracellular matrix [50] and lead to airway remodeling. The elevated release of neutrophil 
proteases has several harmful effects and greatly contributes to the immunopathology seen in 
the CF lung. 
Frustrated CF neutrophils display delayed apoptosis and often undergo necrosis rather 
than clearance by normal apoptotic mechanisms [51]. Decomposing neutrophils release large 
amounts of intracellular contents, which fuel further neutrophil influx and contribute to the 
high viscosity of CF sputum [51-53]. This defect in normal neutrophil death could be due to 
low amount of several counter-regulatory molecules in the CF airway that are important for 
terminating or resolving inflammation [32, 54]. Thus, understanding how to reduce of 
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neutrophil dominated host response in the CF airway is key for designing future therapeutics 
to alleviate the progressive and damaging pulmonary inflammation. 
1.2 PSEUDOMONAS AERUGINOSA PULMONARY INFECTIONS IN CYSTIC 
FIBROSIS 
1.2.1 Adaptation and chronic colonization in the cystic fibrosis airway 
P. aeruginosa is a Gram-negative bacteria that is able to utilize a wide variety of nutrient 
sources allowing it to live in the soil, water and in many tissue types in the human body [55]. 
Although P. aeruginosa is ubiquitous in the environment, it mainly causes disease in 
individuals who have compromised immune systems, thereby classifying it as an 
opportunistic pathogen. The bacterium can cause life threatening infections for individuals 
with severe burns, or implanted medical devices and CF patients, who starting early in life 
are particularly susceptible to P. aeruginosa pulmonary infections [55]. A high proportion of 
CF patients become infected at an early age and have recurrent respiratory infections 
throughout their lifetime [4]. Frequent P. aeruginosa infections and chronic dysregulated 
host responses combine to cause the majority of morbidity and mortality in CF patients [56]. 
The relatively large genome of P. aeruginosa provides enormous phenotypic 
flexibility and allows the bacteria to adapt and thrive in a variety of environments [8, 21]. By 
altering the production of virulence factors and switching to a biofilm mode of growth, the 
bacteria is able adjust to the CF lung environment and persist in the airway. This adaptation 
in the host by P. aeruginosa is demonstrated by the substantial differences in the phenotypes 
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between isolates from acute and chronic infections [57]. These phenotypic changes are 
thought to promote P. aeruginosa survival in the respiratory track by protecting the 
bacterium from host immune responses [56].   
1.2.2 Bacterial pathogenesis and virulence factor production 
P. aeruginosa is equipped with pili and monotrichous flagella, which are important for 
motility, surface attachment, bacterial aggregation and are essential for microcolony 
formation [57-59]. P. aeruginosa acute respiratory infections stimulate robust AEC 
inflammatory responses. AECs produce IL-8 upon TLR stimulation [60, 61]. Furthermore the 
bacteria stimulate the apical release of the eicosanoid hepoxilin A3 from AECs, which 
further promotes transepithelial migration of neutrophils into the lumen [62]. During initial 
acute infection, planktonic bacteria secrete and release multiple harmful proteins, which 
disrupt multiple innate immune responses further promoting the colonization of the CF 
airway [8].  
P. aeruginosa produces an impressive array of secreted virulence factors controlled 
by  complex regulatory circuits and multiple signaling systems [63]. P. aeruginosa secretes 
several proteases including LasA, LasB and PrpL that damage tissues and disrupt defense 
mechanisms. LasA can degrade host surfactant destroy elastin important for many immune 
functions at the epithelial surface and lung expansion and contraction [64, 65]. LasB has been 
shown to cleave collagen, human immunoglobulin and several complement components, [66-
68] and PrpL targets the antimicrobial protein lactoferrin and the iron transporter transferrin 
[63].   
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P. aeruginosa produces lipases LipA and LipC, that target lipids in surfactant or cell 
membranes [69]. The phospholipases PlcH, PlcB and PlcN destroy host mucins [70] and 
work in concert with bacterial rhamnolipids break down host phospholipids. P. aeruginosa 
rhamnolipid has a detergent-like structure that has been proposed to solubilize host 
phospholipids making  them more accessible for cleavage [71]. While rhamnolipid secretion 
is traditionally not categorized as a virulence mechanism, it can inhibit AEC ciliary function 
and reduce immune cell function and cause neutrophil necrosis, further promoting bacterial 
colonization [72].  
Most P. aeruginosa strains secrete pyocyanin, and high concentrations are detected in 
CF patient secretions and negatively correlate with lung function [73-76].  Pyocyanin is 
proinflammatory, impairs ciliary function and macrophage efferocytosis [77], while also 
being antimicrobial to other bacterial species, thereby likely promoting P. aeruginosa ability 
to outcompete other organisms in the CF lung [78-80]. It also has a pigment that gives blue-
green color to the bacterial colonies, making it fun for graduate students and technicians to 
plate delightful P. aeruginosa LB agar birthday cakes.  
A Type III secretion system is a major determinant of P. aeruginosa virulence that 
through a needle like aparatus injects the exotoxins ExoS, ExoU, ExoT and ExoY directly 
into host cells [56, 81]. Nearly all strains express one of the two major exotoxins ExoU or 
ExoS but rarely both while the most strains express ExoT [82]. ExoS and ExoT work in 
concert to inhibit actin polymerization, prevent phagocytosis and promote apoptosis [83]. 
ExoY can increase membrane permeability and also target actin polymerization [84]. ExoU 
is a phospholipase that causes rapid death of host cells due to loss of plasma membrane 
integrity [85]. Together these P. aeruginosa virulence factors dramatically disrupt normal 
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mucosal function in the lung by damaging host cells and preventing bacterial clearance 
thereby allowing the microbe to establish infection in the airways [86].  
Interestingly, many virulence mechanisms are reduced or turned off during chronic 
infection in the CF lung [70, 87, 88]. The reduction of virulence factor production does not 
result in enhancing host clearance of the bacteria instead these changes facilitate long-term 
colonization in the host. As the bacteria adapt to their environment they undergo many 
phenotypic modifications that save energy and allows for persistence in the CF lung [89]. 
Both the upregulation of antibiotic efflux pumps and the downregulating many metabolic 
pathways during chronic infection make P. aeruginosa refractory to host defenses and many 
antimicrobial treatments compared to their planktonic counterparts [90]. These phenotypic 
alterations further highlight how P. aeruginosa can sense the surrounding environment and 
adapt to different niches.  
1.2.2.1 CFTR inhibitory factor (Cif) 
The secreted protein Cif (PA2934) was first identified as a P. aeruginosa virulence factor 
due to its capability to decrease plasma membrane expression of CFTR on human AECs [91, 
92]. P. aeruginosa can secrete the Cif protein either directly into the surrounding 
environment or in outer membrane vesicles (OMVs) [93]. The packaging of bacterial 
proteins into OMVs facilitates delivery across dense mucus and long distances in the airways 
to then fuse with host cells and deliver their cargo into the cytoplasm [94]. Cif also regulates 
epithelial TAP1 ubiquitination to reduce MHC class I antigen presentation and the apical 
expression of the drug efflux ABC transporter P-glycoprotein on a variety of cell types [92, 
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95]. These studies demonstrate that Cif acts to alter host defense in several ways during P. 
aeruginosa infection. 
Cif is an α/β-hydrolase with epoxide hydrolase activity which is important for Cif 
mediated effects on CFTR [91, 96, 97]. The protein has an unusual active site and is the first 
epoxide hydrolase described in its class [97, 98]. Cif can catalyze the hydrolysis of 
environmental epoxides [99] and interestingly, the regulation of Cif packaging into OMVs 
can be altered when the P. aeruginosa is grown in the presence of specific epoxides [100]. 
However, Cif’s epoxide hydrolase activity in CF pathogenesis and the identity of possible 
host epoxide substrates needs further investigation.  
Cif is expressed by P. aeruginosa clinical isolates and is detected in CF patient 
sputum [91, 99]. Recently Cif homologs have been identified in other airway pathogens, 
including Acinetobacter nosocomialis and Burkholderia cepacia, which also display epoxide 
hydrolase activity and reduction of CFTR abundance in AECs [101]. Therefore, bacterial 
epoxide hydrolases maybe a class of secreted virulence factors that are shared by several 
pulmonary pathogens.  
1.2.3 Chronic infection and biofilm production 
In the CF lung, the conversion of P. aeruginosa acute infection to chronic colonization often 
involves the development of bacterial biofilms. Biofilms are bacterial communities that are 
attached to living or abiotic surfaces, surrounded by extracellular matrix produced by the 
bacteria and often include DNA, polysaccharides and proteins [97, 101]. These communities 
develop in a well-coordinated manner that involves sensing and responding to environmental 
cues such as bacterial cell density and nutrients [102]. P. aeruginosa biofilms reside in the 
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mucus layer overlying AECs in the CF airway causing further obstruction, respiratory failure 
and eventual loss of pulmonary function at a young age [103-105].  
To build a biofilm, P. aeruginosa must first attach to the surface and form a 
microcolony [106, 107].  The development of a biofilm is intricately linked to population 
density and the bacteria produce small membrane diffusible molecules to sense critical mass 
known as quorum sensing [61]. The accumulation of these molecules signal to the bacteria to 
then undergo phenotypic alterations that include downregulation of flagella and virulence 
factors such as type 3 secretion systems [104]. The bacterial aggregates then produce 
abundant extracellular polymeric substances (EPS), mainly composed of polysaccharides, 
DNA, lipids and proteins, which imparts a physical shield and helps to protect the bacterial 
from mechanical forces [63]. The generation of EPS and unregulation of efflux pumps help 
to shelter the bacteria from antibiotics, host defense molecules and phagocytosis [108], 
making P. aeruginosa biofilms extremely difficult to treat [55, 109-111]. Accumulating 
evidence suggests that persistence of P. aeruginosa biofilms contribute to chronic 
inflammation, which causes extensive damage to the lung tissue and plays an important role 
in the decline of pulmonary function [8, 55, 112].  
Frustrated neutrophil responses also contribute to the biofilm formation through the 
release of DNA, actin and granule proteins from necrotic cells [53, 113]. F-actin and DNA 
released from neutrophils enhance P. aeruginosa biofilm architecture. DNAse treatment 
reduces biofilm formation and the therapeutic Pulmozyme (rhDNase I) has been shown to be 
effective in reducing bacterial colonization and improving mucociliary clearance in the CF 
patient airways [114, 115]. 
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1.3 VIRAL BACTERIAL CO-INFECTION IN CYSTIC FIBROSIS 
Respiratory viral infections in CF patients have been shown to be associated with increased 
hospitalization and decline in pulmonary function [116-119]. However, few studies have 
investigated if CFTR deficiency affects viral clearance mechanisms. While the incidence of 
viral infection is not elevated CF patients, the duration and severity of the illness is 
intensified [120]. Respiratory syncytial virus (RSV), influenza, and rhinovirus are the most 
commonly detected viruses in CF patients and their occurrence significantly correlates with 
disease progression and pulmonary exacerbation [121, 122]. A prospective study over a five-
year period showed 50% of CF respiratory exacerbations requiring hospitalization were 
associated with the isolation of a respiratory virus [121]. Furthermore, viral pathogens have 
been detected in 46% of children and 33% of adults with CF during pulmonary exacerbation 
[123]. RSV represents 9-58% of all reported viral infections in CF with the highest incidence 
in young children [124, 125]. Studies indicate that RSV infection in CF patients increases 
hospitalization rates up 14.6% and note a greater decline in lung function among infants with 
CF with a history of RSV-related hospitalization than those who did not require admission 
[123]. Although clinical studies demonstrate clear associations between viral infections and 
poor pulmonary outcomes, the underlying cellular mechanisms and immunopathology that 
contributes to morbidity in CF remain unclear. 
Clinical studies show an association between respiratory viral infections in CF and 
the development of chronic P. aeruginosa infection [116, 123-128]. The first isolation of P. 
aeruginosa in CF patients occurs in higher frequency during the winter months, which 
temporally correlate with the peak of incidence of many respiratory viral infections [116, 
123-128]. In addition, 85% of new P. aeruginosa colonization in CF patients followed a viral 
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infection within 3 weeks [116].  Moreover, during a respiratory viral infection, CF patients 
show an impaired ability to clear P. aeruginosa. Although a variety viruses that are isolated 
from CF patients, RSV is reported to be the most common respiratory virus associated with 
the development of chronic P. aeruginosa infection in CF patients [117].  
RSV preferentially infects ciliated epithelial cells and causes bronchiectasis and 
airway obstruction. Although the prevalence of the virus is widespread there is a failure to 
develop natural immunity to infection. In recent years Palivizumab prophylaxis for RSV 
infections has been developed and a studies have investigated its use in CF populations [129-
131]. These inital small studies indicate that overall hospitalization rates are reduced 
following administration of Palivizumab in CF patients, however, P. aeruginosa colonization 
rates remained the same or in some cases, were reported to be higher [129-131]. This could 
be due to the Palivizumab targeting antigenic regions of the F protein that are preferentially 
expressed after virus has entered the cell and suggests that newer vaccine that target the pre-
fusion F protein or nanobodies delivered intranasally could be more efficacious [132]. A 
different approach to combating immunopathology following respiratory viral infections is to 
target the host response to viral pathogens. Therefore studies directed towards understanding 
host inflammatory responses to respiratory viral infections and as well as developing 
therapeutics that target detrimental host responses, will continue to be essential line of 
investigation. 
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2.0 TRAFFIC CONTROL: THE INTERSECTION OF LIPID MEDIATORS, 
INFECTION AND CHRONIC INFLAMMATION IN THE LUNG   
 2.1 GENERATION AND ANTI-INFLAMMATORY FUNCTIONS OF 
EICOSANOIDS  
Lipids have a crucial role in cellular function, forming membranes, as well as acting as 
cellular signaling molecules. Arachidonic acid (AA) is a major constituent of the mammalian 
phospholipids and together with its wide range of metabolites (termed eicosanoids), play a 
substantial role in lipid signaling, including modulation of the innate immune response [133]. 
When AA is released from membrane phospholipids it can then be metabolized by 
cyclooxygenases (COX), lipoxygenases (LOX), monooxygenases (CYP450), which results 
in the generation of a broad range of bioactive lipid mediators called eicosanoids. There are 
four main classes of eicosanoids: prostaglandins, prostacyclins, thromboxanes and 
leukotrienes. 
Cyclooxygenases catalyze the insertion of two oxygen atoms in AA [134] and in 
mammalian cells, two isoforms exist, COX-1, which is constitutively expressed, and COX-2, 
which is inducible [133]. The initial reaction of AA oxidation, mediated by COX, yields 
prostaglandin G2 (PGG2). PGG2 is reduced to prostaglandin H2 (PGH2), which serves as a 
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precursor for various other immunomodulatory compounds, including prostaglandins, 
thromboxanes and Prostaglandin E2 (PGE2) [133].  
Lipoxygenases (LOX) are a large group of dioxygenases that catalyze oxygen 
insertion into polyunsaturated fatty acids in animals, plants as well as microorganisms [135, 
136]. LOX catalyze the synthesis of leukotrienes, lipoxins and hepoxilins through the 
combination of various enzymatic activities [133, 135]. Various isoforms of LOX exist with 
different stereospecificity and activities that catalyze oxygenation and hydroperoxidation of 
PUFAs at the various carbon positions on the AA backbone.  
Many LOX products have been implicated in both pro-inflammatory and anti-
inflammatory responses. Both hydroperoxy-eicosatetraenoic acids (HpETEs) and hydroxy-
eicosatetraenoic acids (HETEs) which are intermediate products can lead to the formation of 
either pro-inflammatory or pro-resolving lipid mediators [137]. The interaction of COX- and 
LOX-derived lipid mediators, as well as the combination of these two pathways, leads to the 
antagonisim of the inflammatory response [137]. PGE2, a COX-derived eicosanoid has also 
been argued to induce the expression of both 12-LOX and 15-LOX in neutrophils. 
Furthermore, the non-steroidal anti-inflammatory drug aspirin, was shown to acetylate COX 
isozymes leading to the formation of 15(R)-HETE, which acts as LOX substrate for the 
formation of the specialized pro-resolving lipid mediators (SPM) lipoxins (LXA4) [138]. 
Therefore, depending on the environmental cues, COX and LOX enzyme can produce lipid 
mediators that either promote or antagonize inflammation.  
In addition to these pathways, cytochrome P450 enzymes (CYP450) can metabolize 
AA to form epoxyeicosatetraenoic acids (EETs). CYP450 are epoxygenases that can insert 
an oxygen atom on any of the four double bonds of arachidonic acid and the double bond is 
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reduced as the epoxide is formed. Four regioisomers, 5,6-, 8,9-, 11,12- and 14,15-EET can be 
formed by CYP450 epoxidation, and although many CYP450 enzymes can produce multiple 
regioisomers, one is usually predominates [139]. 
Much of the research regarding EETs has focused on their cardioprotective functions, 
including induction of the endothelium-derived hyperpolarizing factor that decreases blood 
pressure [140-142]. Studies indicate that EETs have additional potentially beneficial effects 
on the vascular system, heart, kidneys, and nervous system, and many current studies are 
directed at these actions [140-143]. Soluble epoxide hydrolases (sEH) converts EETs to 
dihydroxyeicosatrienoic acids (DHETs) and attenuates many of the functional effects of 
EETs [144]. Therefore, sEH inhibition or EET mimicry as a therapeutic strategy for 
increasing the beneficial effects of EETs is currently being investigated [140, 144, 145]. 
EETs also have anti-inflammatory properties [146]. 8,9-EET, 11,12-EET, and 14,15-
EET inhibit endothelial apoptosis and maybe important in renal inflammation [147]. The 
addition of 8,9-EET or 11,12-EET inhibited basal TNFα secretion from monocytes (THP1) 
by about 90% and 40%, respectively [148]. 11,12-EET, but not 14,15-EET, was shown to 
inhibit adherence of monocytic cells to vascular endothelium in an ex vivo model and 
inhibition of adherent cells was comparable to that of treatment with a blocking VCAM-1 
antibody [146]. The anti-inflammatory effect of all EET regioisomers in endothelial cells is 
mediated by to PPARγ inhibition of NF-κB activation [149]. 14,15-EET treatment reduces 
inflammation in human bronchi and has antiapoptotic actions in the endothelium [143, 150], 
and more recently has been implicated in promoting the generation of pro-resolving lipids 
[151]. 
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The effects of eicosanoids on mammalian cells are dependent on the type of target 
tissue and the physiological state of these tissues [137]. Considerable research is being done 
to determine the role eicosanoids play in the host during sterile, allergic and microbial-
induced inflammation and more recently, whether they can enhance the clearance of 
pathogens.  
 2.2 PRO-RESOLVING EICOSANOID MEDIATORS AND PULMONARY 
DISEASE 
Prolonged inflammation contributes to the pathogenesis of many diseases and pathology. 
Loss of tissue or organ function as a result of an inappropriate inflammatory response is also 
seen in various pulmonary diseases, such as chronic bronchitis, emphysema, asthma, and 
CF. Lipoxins (LXA4) are potent anti-inflammatory molecules that promote the resolution of 
inflammation and the return to tissue homeostasis [152]. They are generated endogenously 
during what is called “class switch” when COX and LOX enzymes reduce the production of 
inflammatory lipid mediators and instead switch to generate pro-resolving lipid mediators 
[153]. 
LXA4 is synthesized by the oxygenation of AA by 15-LOX which generates 15-
SHpETE in epithelial cells. Neutrophils or monocytes, which carry 5-LOX, metabolize 15-
HpETE into 5(6)-epoxytetraene which is rapidly converted by LTA hydrolase to generate 
LXA4 [154]. 15-epi lipoxin A4 (15-epi LXA4), an epimer of LXA4, has a different 
biosynthetic pathway. The acetylation of COX-2 oxygenates AA at the 15 position to 
generate 15-RHETE, which is then further metabolized by 5-LOX [154].  The acetylation of 
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COX2 by the addition of aspirin can occur in many cell types to produce 15-RHETE. 
However, immune cells such as neutrophils or monocytes that carry both COX2 and 5-
LOX, can synthesize 15-epi LXA4 without the addition of extracellular 15-HETE [154].   
 
Modified from Ryan and Godson, 2010  
 
The proper clearance of neutrophils is important for the resolution of inflammation. 
Both LXA4 and 15-epi LXA4 regulate many neutrophil functions that help promote the return 
to tissue homeostasis [152, 155, 156]. They have been found to inhibit neutrophil 
chemotaxis, degraulation and entry into inflamed tissues in animal models [157-159]. Also 
the generation of LXA4 and 15-epi LXA4 can inhibit LTB4 formation and neutrophil 
adherence [156, 160]. Furthermore, binding to their receptor ALX/FPR2 on neutrophils, 
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LXA4 and 15-epi LXA4 oppose acute-phase protein serum amyloid A signaling, which 
prolongs neutrophil longevity by suppressing constitutive apoptosis [161, 162].  
In contrast to their inhibitory effects on neutrophil and eosinophil recruitment, LXA4 
are potent chemoattractants for monocytes [163]. LXA4 also promote the phagocytic 
clearance of apoptotic cells by macrophages, which might contribute further to the resolution 
of inflammation. LXA4 stimulates monocyte adherence to vascular endothelium and 
chemotaxis [164]. Interestingly, LXA4 recruited monocytes do not generate superoxide 
anions or degranulate in the presence of LXA4. Therefore, both 15-epi LXA4 and LXA4 have 
a crucial role in resolving inflammation by regulating neutrophil accumulation and recruiting 
monocytes to clear the inflamed site of necrotic and apoptotic neutrophils [163]. 
Patients with chronic pulmonary inflammatory diseases have higher levels of pro-
inflammatory mediators and lower levels of mediators that contribute to the resolution of 
inflammation [152]. For example asthma patients have reduced LXA4 in their airways, which 
correlate with sEH activity [151]. Administering 15-epi LXA4 to asthma animal models has 
shown a significant decrease in airway hyper-responsiveness and inflammation [165]. 
Chronic obstructive pulmonary disease is another airway inflammatory disease associated 
with long-term exposure of the lungs to irritants like cigarette smoke and other pollutants 
found in the air. In chronic obstructive pulmonary disease, there is an overexpression of C 
reactive protein and serum amyloid A, which may be alleviated with the administration of 
LXA4, [152, 166, 167]. CF patients also have reduced levels of LXA4 in their airway 
secretions [54]. However, when IV antibiotics was administered for two weeks CF patients 
saw an increase LXA4 in sputum and reduced IL-8 in serum [168]. These results indicate that 
in CF, infection status might play a role in decreasing LXA4 generation in the airways.  
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2.3 P. AERUGINOSA AND INTERACTIONS WITH HOST LIPIDS 
P. aeruginosa  pulmonary infection is associated with an overproduction of PGE2. This 
increase in PGE2 is due to the large amount of AA released during P. aeruginosa infection, 
mediated by ExoU, an intracellular phospholipase [169, 170]. The elimination of ExoU 
diminished severity of inflammation and PGE2 production in a mouse model and on epithelial 
cells [170, 171].  Furthermore, the P. aeruginosa quorum sensing molecule, 3-oxo-HSL, 
induces COX-2 and PGE2 production in human lung fibroblasts [172]. This demonstrates that 
the bacteria can release PGE2 by two methods to further enhance and manipulating 
inflammatory pathways in the host. Interestingly, a recent study showed that LXA4 is an 
inhibitor of the quorum sensing receptor LasR and decreases the bacteria’s release of 
pyocyanin [173]. This study suggest that treatment with LXA4 could not only disrupt P. 
aeruginosa bacterial cell communication, but also prevent the bacterial biofilm growth and 
chronic infection [174]. 
Although the presence of LOX in plants and animals has long been known, their 
presence in lower eukaryotes and prokaryotes has only recently been established. P. 
aeruginosa  possesses a secretable 15-LOX (LoxA) capable of producing 15-HETE [175]. It 
has been postulated that the generation of 15-HETE by LoxA increases the biosynthesis of 
LXA4 and promotes an anti-inflammatory state. The biosynthetic pathway for LXA4 
generation derived from 15-HETE requires an additional two enzymes 5-LOX and LTA/B 
hydrolase to complete the synthesis [154]. P. aeruginosa does not produce either of those 
enzymes and would have to rely on the host neutrophils or monocytes to produce either 
LXA4 (or LXB4). Currently there is no direct evidence that supports P. aeruginosa enhances 
LXA4 production. Moreover, a recent study demonstrated that LoxA does not interact 
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directly with 15-HETE or 5-HETE, suggesting that it is unlikely that LoxA regulates lipoxin 
production [176]. The production of 15-HETE, while important for generating SPMs, is also 
linked to the promotion of airway inflammation and mucus production [177]. It is possible 
that P. aeruginosa has evolved the ability to generate 15-HETE to increase inflammation in 
the lung or manipulate the environment to promote chronic infection (See Appendix A). 
2.4 PRO-RESOLVING LIPID MEDIATORS AS THERAPIES FOR INFECTIOUS 
INFLAMMATION 
Understanding how pro-resolving lipid mediators play a role in the acute inflammatory 
response to microorganisms is an expanding area of interest. Current drug regiments for 
infectious disease are either antibiotics that target a particular pathogen or 
immunosuppressive therapies for chronic inflammatory conditions. Treatment with SPMs 
could be a novel host protective approach to resolve aggressive infectious inflammation 
rather than the traditional therapies that dampen immune responses.  
Several studies have demonstrated that SPM can stimulate antimicrobial activities at 
epithelial surfaces. Bactericidal permeability increasing protein (BPI) production in intestinal 
epithelium was enhanced following treatment with a 15-epi LXA4 analogue and was shown 
to decrease S. typhimurium bacterial burden [178]. Resolvin E1 treatment of gut epithelial 
cells induces intestinal alkaline phosphatase, which detoxifies bacterial LPS in the gut [179]. 
These studies show that SPM treatment can enhance natural host defense against bacterial 
pathogens. 
A few investigations demonstrate that utilizing LXA4 analogues can reduce bacterial 
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burden and pathogen associated inflammation. Periodontitis is caused by an overgrowth of 
resident Gram-negative bacteria in the oral cavity and mucosal inflammation. In 
Porphyromanas gingivalis infection models the introduction of stable analogues of LXA4 
result in a reduction of neutrophil recruitment to the site of infection [180]. Also 
administration of a LXA4 analog in mice challenged intratracheally with P. aeruginosa 
reduced neutrophil infiltration, weight loss, and bacterial burden [54]. These studies indicate 
that SPM treatment could be helpful in targeting bacterial pathogens and lessening of disease 
severity.  Furthermore, supplementing current therapies with SPMs might be a one-two 
punch for bacterial organisms. For example, the SPM resolvin D1, was shown to protect 
mice in an Escherichia coli infection model by enhancing host antimicrobial responses and 
accelerated the resolution and bacterial killing, as compared to antibiotics alone [132].  
More recently, SPM administration has been explored as a treatment for viral 
infection. The SPM protectin D1 has been shown to inhibit influenza infection in mice and 
improve survival even when administered as late as 48 hours after infection [107].  Another 
SPM, resolvin D1, reduced herpes associated ocular stromal keratitis pathology [181]. Some 
of these studies postulate that SPM treatment inhibits viral replication however, more work is 
needed to confirm these observations. 
Unfortunately, SPM treatment may not always be beneficial for resolving all 
infectious disease. For example the pathogens Mycobacterium tuberculosis and Toxoplasma 
gondii favor the generation of LXA4, most likely to promote immune evasion [182, 183]. The 
fungal pathogen Candida albicans can biosynthesize its own resolvin E1 that limits IL-8-
mediated neutrophil infiltration in the host enabling colonization [184]. These examples 
further illustrate the complicated relationship between the host response and microbial 
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adaptation and survival in an inflammatory environment. Further work is needed to 
understand how either exogenous administration or host SPM production controls immune 
responses to pathogens. 
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3.0 PSEUDOMONAS AERUGINOSA SABOTAGES THE GENERATION OF HOST 
PRO-RESOLVING LIPID MEDIATORS  
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3.1 INTRODUCTION 
Recurrent P. aeruginosa infections coupled with robust, damaging neutrophilic inflammation 
are characteristic of the chronic lung disease cystic fibrosis (CF) [21]. CF is caused by 
mutations that impair the function of the cystic fibrosis transmembrane conductance 
regulator (CFTR), an anion channel that controls epithelial fluid and ion homeostasis. The 
resulting failure of mucociliary clearance in the CF lung allows microorganisms to repeatedly 
infect the respiratory tract [8]. These bacterial infections incite robust inflammatory 
responses, dominated by elevated pro-inflammatory cytokines and continued accumulation of 
neutrophils in the CF airway [21]. However, these responses are ineffective at clearing 
pathogenic microbes in the CF lung [185], instead creating a hyper-inflammatory cycle that 
leads to host-tissue damage, respiratory failure, transplant or death.  
Most adult CF patient airways are chronically infected by the opportunistic bacterial 
pathogen Pseudomonas aeruginosa, which is a major cause of morbidity and mortality. P. 
aeruginosa thrives in the hyper-inflammatory CF lung, forming biofilms that are 
mechanically robust and resistant to clinically achievable levels of antibiotics [8]. P. 
aeruginosa also persists in the airways by interfering with host defense via secreted bacterial 
virulence factors and small molecules [8]. We recently showed that P. aeruginosa secretes 
the CFTR inhibitory factor (Cif), an epoxide hydrolase that triggers the degradation of ABC 
transporter family members, including CFTR [91, 92, 95, 97, 98]. Cif transcripts have been 
observed in CF patient sputum and clinical isolates from CF patients confirm that P. 
aeruginosa expresses Cif during pulmonary infection [91, 100]. Nonetheless, a role for Cif’s 
epoxide hydrolase activity in CF pathogenesis and the identity of possible host epoxide 
substrates remains unclear.  
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Following a pathogenic insult, the host rapidly releases polyunsaturated fatty acids 
from cell membranes and converts them into various lipid mediators that either stimulate or 
inhibit inflammation. The correct balance of these signals is required to optimize pathogen 
clearance while minimizing collateral damage to host tissues, and perturbations in either 
direction can be deleterious [137]. Among these lipid mediators, arachidonic acid-derived 
eicosanoids, including epoxides, play important roles. Although many eicosanoids induce 
pro-inflammatory cascades, recent studies have also identified immunomodulatory and pro-
resolving functions [167, 186]. In particular, lipoxins decrease neutrophil extravasation and 
enhance macrophage efferocytosis, thus promoting the resolution of inflammation and a 
return to tissue homeostasis [164, 187]. In the CF lung, the concentration of lipoxin A4 
(LXA4) is significantly reduced, suggesting that a failure to activate pro-resolving 
mechanisms contributes to excessive inflammation in the airway [54].  
In this study, we show that Cif selectively converted an endogenous epoxide-
containing eicosanoid 14,15-epoxyeicosatrienoic acid (14,15-EET) to its corresponding diol, 
destroying the signal that triggers increased biosynthesis of the specialized pro-resolving 
mediator 15-epi LXA4. The translational relevance of this unexpected biochemical virulence 
activity to clinical CF was investigated by retrospective analysis of bronchoalveolar lavage 
fluid (BALF) samples and suggested that Cif contributes to the hyper-inflammatory 
environment of the chronically infected CF lung. 
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3.2 METHODS 
Epithelial cell culture. The immortalized human CF bronchial epithelial cell line 
CFBE41o− (referred to here as CFBE cells) were a gift from Dr. J.P. Clancy (University of 
Cincinnati). CFBE cells were seeded on 0.4µM polyester Transwell filters (Corning) and 
coated with collagen and fibronectin and grown at air-liquid interface for at least 7-10 days, 
as previously described [93].  Primary human CF AECs (CF HBEs) acquired from the 
University of Pittsburgh Airway Cell and Tissue Core were cultured from CF patient 
explanted lungs using an Institutional Review Board approved protocol at the University of 
Pittsburgh (IRB# 11070367), described in [188]. CF HBEs were cultured on collagen-coated 
Transwell filters (Corning) for 4-6 weeks at air-liquid interface (ALI) prior to use in 
experiments.  
 
Bacterial strains and culture conditions. Pseudomonas aeruginosa strains PA14 and 
PA14∆cif (gifts from Dr. George O’Toole, Geisel School of Medicine at Dartmouth) [91, 
189] were used in this study. Dr. Jane Burns at the University of Washington provided 
pulmonary Pseudomonas aeruginosa clinical isolates from CF patients [57]. Overnight 
cultures grown in LB were washed and diluted in minimal essential medium (Gibco) 
supplemented with 2mM glutamine to an OD600 of 0.5.  Epithelial cells were inoculated with 
~7x106 bacteria, corresponding to a multiplicity of infection of 25.  
 
Protein Expression and Purification. Wild type Cif protein (Cif-WT) and the Cif-D129S 
and Cif-E153Q mutants were expressed as described previously [96, 190, 191]. Briefly, 6-
His tagged Cif, Cif-D129S, and Cif-E153Q were expressed from an arabinose-inducible 
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vector in TOP10 E. coli cells. The proteins were isolated using nickel-affinity purification, 
concentrated, and dialyzed into PBS. 
 
Cif secretion by clinical isolates. P. aeruginosa paired clinical isolates [57] grown overnight 
in LB were washed and diluted in minimal essential medium supplemented with 2mM 
glutamine to an OD600 of 0.5. Polarized CFBE cells were inoculated with ~7x106 bacteria and 
incubated 37˚C. After 5 hours, apical supernatants were collected, spun down to remove 
planktonic bacteria and the supernatants were transferred to a new tube. The samples were 
frozen on dry ice and stored at -80˚C.  
High binding 96 well ELISA plates (Costar) were coated with 100µl of anti-Cif (used 
in earlier studies) polyclonal antisera diluted 1:12,000 in PBS containing 35mM sodium 
carbonate and 70mM bicarbonate overnight at 4˚C. The plate was blocked with PBS, 1% 
BSA for 1.5 hours at room temperature and washed three times with PBS, 0.05% Tween 20 
prior to the addition of sample. 100µl of either unknown sample was added to the plate along 
side purified Cif-WT which serially diluted and utilized as a standard curve. The plate was 
incubated at room temperature for 2 hours. After removing unbound sample with three 
subsequent wash steps, 100µl of detection of recently generated anti-Cif DM163 antibody 
diluted 1:4000 in PBS was added to the plate and incubated for 2 hours at room temperature. 
The detection antibody, anti-Cif HRP, was conjugated prior to the day of the assay to HRP 
using a conjugation kit (Abcam). The plate was developed with 15-20 minutes incubation 
with TMB substrate followed by the addition of 2M sulfuric acid stop the reaction. The plate 
was read at 450nM on a SpectraMax M2 plate reader and the concentrations were determined 
using a standard curve of purified Cif. 
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In vitro Hydrolysis Assay. Hydrolysis of the epoxyeicosatrienoic acids by Cif was measured 
using an adrenochrome reporter assay [101, 192]. Briefly, 40 μM Cif protein was incubated 
separately with 1 mM of each epoxyeicosatrienoic acid regioisomer (Cayman Chemical) in 
2% DMSO in PBS at 37˚C for 60 minutes. The reactions were quenched with NaIO4 in 90% 
acetonitrile to a final concentration equimolar to initial EET concentrations and incubated at 
room temperature for 30 minutes. Epinephrine was added in excess to react with the residual 
NaIO4.  A490 values were measured and compared to a standard curve generated with 14,15-
DHET.  
Crystallographic structure of Cif with 14,15-EET. Cif-E153Q:14,15-EET co-crystals were 
obtained by vapor diffusion against 400 µL of reservoir solution in a 4 µL hanging drop at 
291 K [190, 191]. 5 mg/mL Cif-E153Q protein in PBS was incubated with neat 14,15-EET at 
277 K overnight. The mixture was added in a 1:1 ratio with reservoir solution consisting of 
12% (w/v) polyethylene glycol 8000, 200 mM CaCl2, and 100 mM sodium acetate (pH 5). 
Prior to data collection, crystals were washed in cryoprotectant solution consisting of 12% 
(w/v) polyethylene glycol 8000, 200 mM CaCl2, 100 mM sodium acetate (pH 5), and 20% 
(w/v) glycerol and flash cooled by plunging into a liquid nitrogen bath. Oscillation data were 
collected at 100 K at the X6A beamline of the National Synchrotron Light Source at 
Brookhaven National Laboratory. Diffraction images were processed and scaled with the 
XDS package (v December 6th, 2010) [193]. Molecular replacement with the Phenix suite (v 
1.10.2055) used the apo-Cif-WT structure (PDB ID 3KD2) as the search model and revealed 
two dimers in the asymmetric unit [194-196]. Iterative rounds of automated and manual 
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refinement were carried out with Phenix and WinCoot (v 0.7), respectively. The adducted 
ligand was included in the model after two rounds of automated and manual refinement, and 
before the placement of waters. Final coordinates were deposited to the Protein Data Bank 
(PDB ID 5JYC). Pymol (www.pymol.org) was used to render structure images of the final 
model of chain D, in which the active-site structures are best defined. 
 
14,15-EET quantification from airway epithelial cell secretions. Polarized epithelial cells 
were exposed to 1 ng/ml of TNFα (R&D systems) in minimal essential medium (Gibco) 
supplemented with 2 mM glutamine for 24 hours prior to apical treatment with either 1 µM 
of purified Cif protein 45 minutes or 7x106 bacteria for 5 hours at 37˚C with 5% CO2. The 
apical supernatants were collected and immediately added to 3 volumes of cold HPLC-grade 
methanol (Fisher Chemical), layered with N2, and stored at -80˚C. To identify 14,15-EET 
concentrations in the apical secretions, the samples were acidified to a pH of 4 and solid-
phase lipid extracted using C18 Sep-Pak cartridges (Waters) as previously described [151, 
197, 198]. The methyl formate (Sigma) fraction was collected, brought to dryness under a 
gentle stream of N2 and resuspended in 1 ml of methanol prior to quantification by ELISA 
(Detroit R&D). Prostaglandin B2 (100 ng) was added to each sample as an internal standard 
and monitored by HPLC to control for variances in extraction recovery. Additionally, 14,15-
EET concentrations in apical supernatants were confirmed by liquid chromatography mass 
spectrometry using previously described techniques [199, 200].   
 
Neutrophil isolation. Neutrophil (polymorphonuclear leukocytes or neutrophils) were 
obtained by venipuncture from volunteers who had given written informed consent to a 
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protocol approved by University of Pittsburgh IRB Committee (IRB# PRO14070447). 
Neutrophils were isolated from heparinized peripheral blood, by dextran (Sigma) 
sedimentation followed by a histopaque (Sigma-Aldrich) gradient [201]. Following RBC 
hypotonic water lysis neutrophils were washed, counted and resuspended to 2x107 cells/ml in 
phosphate buffered saline without calcium and magnesium (referred to here as PBS-/-). Only 
neutrophil preparations that exceeded 90% viability by trypan blue exclusion were used in 
experiments.   
Quantification of neutrophil generation of LXA4 and 15-epi LXA4. 1x106 neutrophils 
were resuspended in 0.15 ml of phosphate buffered saline with 1mM calcium chloride and 
0.5 mM magnesium chloride (PBS+/+) (Gibco) and incubated for 15 minutes at 37˚C with 1 
µM 14,15-EET (Cayman Chemical) in the presence of 5 µM A23187 (Sigma). In some 
conditions 14,15-EET was previously incubated with 1 µM Cif-WT or Cif-D129S at 37˚C 
for 30 minutes prior to neutrophil treatment. The reactions were stopped with 3 volumes of 
ice cold methanol, layered with N2, and stored at -80˚C until solid phase extraction and 
quantification of 15-epi LXA4 by ELISA (Neogen) as previously described [202]. 
Prostaglandin B2 (100 ng) was added to each sample as an internal standard and monitored 
by HPLC to control for variances in extraction recovery.  For neutrophil-airway epithelial 
cell co-culture experiments, 2.5x105 polarized CFBE cells were treated with TNFα (1 ng/ml) 
for 24 hours and apically exposed to 1 µM Cif for 45 minutes prior to the addition of 
1.25x106 neutrophils for 15 minutes. The apical supernatants were collected, added to 3 
volumes of cold HPLC grade methanol, layered with N2, and stored at -80˚C until further 
processed for quantification of both LXA4 and 15-epi LXA4 by ELISA.  
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Neutrophil transepithelial migration. Polycarbonate Transwell filters with 3 µm pores 
were inverted, coated with collagen and fibronectin, seeded with 1x105 CF AECs, and 
allowed to adhere overnight at 37˚C [203]. The following day the filters were moved to a 
sterile 24-well tissue culture plate with 0.5 ml of medium added to the apical chamber and 
0.1 ml to the basolateral compartment. After allowing the cells to grow to confluency for 3 
days, apical medium was removed and the cells were grown at air liquid interface for 7 days. 
CF AECs were washed with PBS+/+ and allowed to calibrate for 1 hour prior to the 
application of neutrophils on the basolateral surface. Transepithelial electrical resistance 
(TEER) measurements were conducted to confirm polarization of monolayers.   
Isolated neutrophils were labeled with 3 µM Calcein AM (Life Technologies) in PBS 
without calcium and magnesium (PBS -/-) (Gibco) for 30 minutes at 37˚C in 5% CO2. The 
labeled neutrophils were washed twice and resuspended in PBS+/+ before incubation in the 
presence or absence of 14,15-EET (100 nM), Cif-WT (100 nM) or Cif-D129S (100 nM) for 
45 minutes at 37˚C with 5% CO2. In some conditions neutrophils were incubated in parallel 
with 15-epi LXA4 (100 nM) for 15 minutes at 37˚C with 5% CO2. IL-8 (100 ng/ml) in 
PBS+/+ was applied to the apical chamber 10 minutes prior to the addition of 5x105 of the 
treated neutrophils to the basolateral compartment [204]. After incubating for 2 hours at 37˚C 
the filters were removed and the plate was gently spun at 300 x g for 5 minutes. Neutrophils 
that had migrated to the apical chamber were measured by Calcein AM fluorescence detected 
by a SpectraMax M2 plate reader.  
 
34 
Murine P. aeruginosa pneumonia model. The protocol for animal infection and respiratory 
physiology measurements was approved by the Institutional Animal Care and Use 
Committee of the Geisel School of Medicine at Dartmouth (Hanover, NH) and done in 
accordance with Association for Assessment and Accreditation of Laboratory Animal Care 
guidelines.  
 Mouse experiments were carried out as described previously, with modification [205]. 
Overnight LB cultures of P. aeruginosa were measured by OD600, pelleted and washed twice 
with PBS. P. aeruginosa strains were resuspended to give 1 × 106 viable CFUs in 40 μl PBS. 
Actual inoculum was determined by serial dilution of the input bacterial suspension on 
Pseudomonas isolation agar (Difco). Adult male C57Bl/6J mice, 8–12 weeks old (Jackson 
Laboratories, Detroit, MI), were inoculated with 40 μl (1 × 106 CFU) of P. aeruginosa PA14 
or isogenic PA14 cif-D129S via oropharyngeal aspiration following brief anesthesia with 
isoflourane. At 24 hours after infection, mice were anesthetized with intraperitoneal sodium 
pentobarbital, tracheas were cannulated, and bronchoalveolar lavage fluid (BALF) was 
collected and stored on ice. A portion of the BALF was immediately diluted 1:4 in ice-cold 
methanol and snap frozen for lipid extraction. Lungs were excised, minced, and immediately 
placed either into 1 ml of cold PBS followed by homogenization or stored on ice. Viable 
bacterial counts in lungs were determined by plating serial dilutions of organ homogenate 
onto Pseudomonas isolation agar plates followed by incubation at 37°C for 24 hours. 
Analysis of CF subject BALF. Bronchoalveolar lavage fluid (BALF) was collected 
prospectively over time in a pediatric population followed for management of CF at 
Children’s Hospital of Pittsburgh, in accordance with a protocol approved by University of 
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Pittsburgh IRB Committee (IRB#504067). Documentation of a CF diagnosis as evidenced by 
one or more clinical features consistent with the CF phenotype and one or more of the 
following criteria; sweat chloride equal to or greater than 60 mEq/L by quantitative 
pilocarpine iontophoresis test or two well-characterized mutations in the CFTR gene. The 
seventeen samples analyzed in the current study tested positive for P. aeruginosa infection 
by dot blot using an anti-Pseudomonas antibody (Pierce). Patient BALF was methanol 
trapped and lipid extracted prior to quantification of 15-epi LXA4 by ELISA (Neogen). IL-8 
concentrations were determined using sandwich ELISA (R&D Systems). Cif protein 
quantification was determined by Western blot analysis. BALF samples were separated by 
SDS-PAGE, transferred to PVDF membrane, and detected by Cif-specific rabbit antisera. Cif 
and IL-8 values were normalized and expressed per mg of total BALF protein. As a result, 
overall changes in total protein concentration were factored out, providing a more stringent 
threshold for detection of differences. Pulmonary function testing (PFT) was performed on 
all patients as part of their CF management and the most recent PFT data in relation to the 
bronchoscopy was collected.  
Cif Antisera. Cocalico Biologicals, Inc. provided test bleed sera for initial screening of 
rabbits as a host species for the development of a Cif-specific polyclonal antibody. We 
selected two rabbits with the lowest background sera reaction as determined by Western blot 
against multiple P. aeruginosa strains. Purified protein (500 μl at 4.3 mg/ml) was submitted 
to Cocalico Biologicals, Inc. Animals were initially inoculated at day 0, and boosted on days 
14, 21, 49, 97, 140, and 170. Test bleeds were taken on days 35, 56, 111, and 154. The 
desired level of Cif detection was reached at day 154. Sera were harvested via two 
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production bleeds (days 177 and 184) followed by exsanguination on day 191. The sera that 
was demonstrated to have the most specific activity to purified Cif was DM163 which was 
was aliquoted and stored at -80°. 
 
Statistics. Experimental differences for in vitro assays were evaluated for statistical 
significance by one-way analysis of variance (ANOVA) with a Tukey’s post hoc test 
(GraphPad 6.0 Software).  All in vitro data are shown as Mean ± SD. P < 0.05 was 
considered statistically significant. For the human studies, a Pearson correlation matrix was 
created using the cor package in R from measurements of Cif, 15-epi LXA4, IL8 and 
spirometry values for the 16 patients for whom a complete set of values was available. The 
corrplot package in R was utilized to visualize the results. For statistical analyses pertaining 
to serum antibody titers and the differences between high verses low Cif cohorts, significance 
was determined using the nonparametric Wilcoxon Rank-Sum Test (GraphPad 6.0 Software). 
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3.3 RESULTS 
3.3.1 P. aeruginosa CF clinical isolates secrete Cif when grown in the presence of airway 
epithelial cells 
P. aeruginosa secretes several virulence factors that diminish host immune responses and
facilitate bacterial colonization of the airway [206]. However, once P. aeruginosa inhabits 
the CF lung, the bacteria undergo substantial changes as it adapts to the host environment, 
including the loss of several virulence related molecules [57, 63, 88, 207]. Previous studies 
demonstrated that P. aeruginosa produces the virulence protein Cif in the CF respiratory 
tract, as the protein is detected in patient sputum [99]. To further investigate the temporal 
expression of Cif in the CF host and provide a better understanding of its role in either the 
initial establishment of acute infection or during chronic colonization, we assess Cif protein 
expression. Cif gene expression has been reported to be elevated in non-muciod compared to 
mucoid isolates, suggesting that Cif might important during initial infection and colonization 
[91]. Ten clinical paired pulmonary isolates from CF patients were studied to investigate if P. 
aeruginosa alters Cif protein production overtime in the CF lung [57].  Paired clinical 
isolates were grown parallel with P. aeruginosa laboratory strains in the presence of 
polarized CFBE cells and Cif secretion was determined by sandwich ELISA developed in 
our laboratory in the apical supernatants (Figure 1). As expected, the laboratory strain PA14 
secreted abundant amounts of Cif compared to the laboratory strain PA01, which other 
studies have reported produce lower amounts of Cif [208]. Moreover, the PA14∆Cif mutant 
secreted undetectable levels of Cif, further validating our assay. The majority of the clinical 
isolates tested secreted detectable levels of Cif when cultured in the presence of airway 
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epithelial cells, demonstrating that Cif is a highly conserved virulence factor among bacterial 
isolates from CF patients (Figure 1B).  However, analysis of the paired pulmonary isolates 
tested showed no appreciable difference in Cif secretion between the early or late isolate 
cohorts. Our data indicate that although longitudinal Cif expression may vary in each 
individual patient, overall a majority of P. aeruginosa isolates maintain the capability to 
secrete Cif in the CF lung during chronic infection.  
Figure 1. CF clinical isolates grown in the presence of AECs cells secrete Cif. (A) Quantification of Cif 
protein secretion by P. aeruginosa laboratory strains (grey bars) or paired clinical isolates from CF patients 
(early isolates red bars, late isolate blue bars) following inoculation of CFBE cells. (B) No significant difference 
in Cif secretion is detected among the CF patient isolates when separated into early and late cohorts (C) 
Standard curve of recombinant Cif used to determine protein concentration in a sandwich ELISA.
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3.3.2 Cif specifically hydrolyzed the mammalian epoxyeicosatrienoic acid 14,15-EET 
AECs produce numerous lipid mediators. Via a major cytochrome P450 monooxygenase-
catalyzed pathway, they convert arachidonic acid into epoxide-containing eicosanoids called 
epoxyeicosatrienoic acids (EETs) (Figure 2A) [137]. To assess the ability of Cif to hydrolyze 
these candidate epoxide substrates, we incubated the enzyme with each of the four 
mammalian EET regioisomers, 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET and assayed 
for production of a vicinal diol through a colorimetric assay [98]. Cif hydrolyzed 14,15-EET, 
but did not exhibit detectable epoxide hydrolase activity for any of the other three 
regioisomers (Figure 2C), suggesting selective conversion of 14,15-EET by Cif to the 
corresponding vicinal diol 14,15-dihydroxyeicosatrienoic acid (DHET) (Figure 2B). An 
immunoassay selective for the diol product confirmed conversion of 14,15-EET to 14,15-
DHET by Cif, but not by the structurally conserved mutant Cif-D129S (Figure 2D), which is 
enzymatically inactive [96].  
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Figure 2. Cif selectively hydrolyzes the epoxyeicosatrienoic acid 14,15-EET.  (A) Cellular cytochrome 
P450 enzymes can catalyze the epoxidation of arachidonic acid, a 20-carbon, ω-6, polyunsaturated fatty acid, 
resulting in the biosynthesis of four epoxyeicosatrienoic acid (EET) regioisomers. (B) Cif hydrolyzes the 
epoxide moiety of 14,15-EET converting it to the vicinal diol 14,15-DHET. (C) Incubation of recombinant Cif 
with each of the EET regioisomers demonstrates its ability to selectively hydrolyze 14,15-EET (black bars). 
**** P < 0.0001 for 14,15-EET compared to all other experimental conditions, one-way ANOVA with Tukey’s 
post-hoc test; N≥3; Mean ± SD. (D) 14,15-EET (grey bars) and is hydrolyzed by Cif-WT to 14,15-DHET 
(black bars), but not by catalytic mutant Cif-D129S. *** P < 0.001 and **** P <0.0001; one-way ANOVA 
Tukey’s post hoc test; N≥3; Mean ±SD.
Previous crystal structures show a limited steric volume for the Cif active site [98], 
and almost all previously reported Cif substrates are terminal epoxides, which can enter deep 
into the active site. In contrast, lipid mediators typically carry epoxide groups in the middle 
of an extended carbon chain, and were thus thought unlikely to serve as Cif substrates. To 
41 
investigate how the enzyme nevertheless catalyzes 14,15-EET hydrolysis, we incubated the 
compound with the Cif-E153Q mutant, which can attack substrates with its active-site 
nucleophile, but cannot catalyze the secondary attack required for product release [190]. We 
then crystallized the resulting complex for X-ray diffraction analysis. The refined structure 
showed the expected adduct of the catalytic Asp129 (D129) nucleophile with the 20-carbon 
EET chain attached at the C15 moiety (Figure 3A). Unexpectedly, it also showed that the 
active site could expand at both ends, opening a tunnel through the enzyme to accommodate 
the extended eicosanoid substrate (Figure 3B). The strong preference for 14,15-EET 
presumably reflects the shorter distance in the other regioisomers between the epoxide 
moiety and the terminal carboxylate, which would thus have to be unfavorably sequestered 
within the active site during hydrolysis.  
Figure 3. The Cif active site can expand at both ends providing adequate capacity to hold the extended 
eicosanoid 14,15-EET. (A) Experimental electron density (2mFO-DFC; blue mesh, contoured at 1σ) shows the 
refined position of the covalent enzyme-substrate intermediate formed by nucleophilic attack of Asp129 (D129; 
blue carbons; chain D) on 14,15-EET (yellow carbons).  (B) In the covalently linked structure, several residues 
shift, opening a tunnel through the active site (blue surface area representation) allowing for accommodation of 
14,15-EET (yellow carbons). The active site of the apo enzyme (PDB ID 3KD2) does not contain this tunnel. Its 
boundaries are shown as red dotted lines. Non-carbon atoms are colored by atom type (N=blue; O=red).
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 3.3.3 Cif-WT can hydrolyze of epithelial derived 14,15-EET produced in response to 
inflammation  
To determine whether Cif’s regioselectivity matches the biological epoxides present in the 
airway, we first tested whether polarized immortalized CF airway epithelial cells (CFBE41o- 
hereafter called CFBE cells) produce 14,15-EET in response to inflammatory signals. We 
treated CFBE cells with tumor necrosis factor-α (TNFα) [156] and performed lipid 
extractions on apical supernatants. Eicosanoid levels were determined in parallel by 
immunoassay (Figure 4A) and by mass spectrometry (Figure 4B). Supernatants from CFBE 
cells exposed to TNFα showed a substantial increase in 14,15-EET levels, compared to 
untreated cells. Furthermore, when CFBE cells were exposed to TNFα in the presence of 
purified Cif-WT protein, the apical level of 14,15-EET was reduced to that of unstimulated 
controls, whereas the catalytically inactive Cif-D129S protein had no significant impact on 
14,15-EET levels.  
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Figure 4. Cif-WT hydrolyzed 14,15-EET derived from CF AECs. (A) Recombinant Cif protein hydrolyzes 
14,15-EET produced by TNFα-treated CFBE cells. Treatment of polarized CF AECs with TNFα (1 ng/ml) for 24 
hours stimulates increased apical secretion of 14,15-EET (blue bars or symbols) compared to untreated cells 
(black bars or symbols). CFBE cells were apically treated with either recombinant Cif-WT or Cif-D129S (1 µM) 
for 45 minutes (red or grey bars respectively). Apical secretions were collected in cold MeOH, solid-phase lipid 
extracted and analyzed for 14,15-EET concentrations by ELISA. *** P <0.001; one-way ANOVA with Tukey’s 
post hoc test; N≥3; Mean ±SD. (B) Cif mediated hydrolysis of 14,15-EET derived from CF AECs confirmed by 
LC/MS Mass Spectrometry. CFBE cells were treated with TNFα (1 ng/ml) for 24 hours (blue bars) and then 
exposed to Cif-WT or Cif-D129S (red and grey bars respectively) for 45 minutes. Apical supernatants were 
collected in methanol, lipid extracted and 14,15-EET was measured by LC/MS Mass Spectrometry. Each data 
point represents one replicate, ** P < 0.01; one-way ANOVA with Tukey’s post hoc test; N≥4; Mean ±SD.
We next sought to determine whether P. aeruginosa could utilize Cif activity to 
hydrolyze CFBE-derived 14,15-EET.  CFBE cells were treated with TNFα and exposed to 
strain PA14, or to the corresponding cif deletion strain PA14∆cif [91]. Apical supernatant 
concentrations of 14,15-EET were significantly reduced in the presence of the Cif-producing 
strain PA14, as compared to the TNFα-only control (Figure 5A). To test for reduced 14,15-
EET due to P. aeruginosa cytotoxicity, CF AECs were treated with the P. aeruginosa strains 
used in the aforementioned experiments. Both strains exhibited minimal cytotoxicity 
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following bacterial inoculation during the 5-hour experimental time point also used in the 
above assays (Figure 5C). In each case, the cif deletion mutant (PA14∆cif) had no significant 
effect on the 14,15-EET levels. Similar results were observed for well-differentiated primary 
CF bronchial epithelial cells (CF HBEs) (Figure 5B) and also for the non-CF Calu3 cell line 
(Figure 5D). Interestingly, we detected comparable levels of 14,15-EET secreted by CF and 
non-CF AECs following TNFα treatment, suggesting that both CF and non-CF epithelial 
cells were similarly capable of secreting 14,15-EET in response to an inflammatory stimulus.  
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Figure 5. Cif secreted by P. aeruginosa hydrolyzed 14,15-EET derived from CF and non-CF AECs. (A) 
Cif secreted by P. aeruginosa hydrolyzes 14,15-EET produced by TNFα-treated CFBE cells. CFBE cells were 
inoculated apically with either PA14 or deletion mutant PA14∆cif (MOI=25) for 5 hours (red bars and grey bars 
respectively) and analyzed for 14,15-EET concentrations by ELISA. *** P <0.001 and **** P <0.0001; one-
way ANOVA with Tukey’s post hoc test; N≥3; Mean ±SD. (B) P. aeruginosa hydrolyzes 14,15-EET produced 
by primary CF airway epithelial cells. Primary CF HBE cells were apically exposed to either PA14 or deletion 
mutant PA14∆cif (MOI=25) for 5 hours (red and grey symbols). Apical secretions were collected and analyzed 
for 14,15-EET concentrations by ELISA. Each symbol represents one individual primary donor. * P <0.05 and 
*** P <0.001; one-way ANOVA with Tukey’s post-hoc test; N≥3; Mean ±SD.(C) 5 hour apical treatment of 
PA14 and PA14∆cif displays limited cytotoxicity against CF AECs at 5 hours. Polarized epithelial cells were 
exposed either 1 ng/ml of TNFα for 24 hours or apical treatment with PA14 or PA14∆cif for 5 hours or for 
24hrs. Cell supernatants and whole cell lysates were collected and LDH levels were measured. Data represented 
as percent LDH release compared to untreated cells. (D) Cif hydrolyzes 14,15-EET produced by non-CF AECs. 
Polarized immortalized Calu3 were stimulated with TNFα (1 ng/ml) for 24 hours to generate the apical 
secretion of 14,15-EET (blue bar). The Calu3 cells were subsequently apically treated with either PA14 (red bar) 
or PA14∆cif  (grey bar) for 5 hours or 1 µM Cif-WT (red bar) for 45 minutes. Apical secretions were collected 
in cold methanol, lipid extracted and analyzed for 14,15-EET concentrations by ELISA. ** P < 0.01; one-way 
ANOVA with Tukey’s post hoc test; Data are represented as mean ±SD.
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These results lead us to ask whether the presence of 14,15-EET would affect the 
growth rate of P. aeruginosa strain PA14, which expresses Cif (Figure 6). The 
supplementation of minimal media with 14,15-EET did not enhance or reduce the growth 
rate of PA14, indicating the bacteria do not utilize 14,15-EET as carbon source or conversely 
that 14,15-EET inhibits bacterial growth. Our data demonstrate that the P. aeruginosa 
hydrolase Cif, can efficiently hydrolyze 14,15-EET secreted by either CF or non-CF AECs.  
Figure 6. 14,15-EET does not enhance P. aeruginosa growth in minimal media. P. aeruginosa grown in 
minimal media supplemented with 14,15-EET does not alter growth kinetics. An overnight culture of 
PA14 was subcultured in M63 minimal media without a carbon source at a starting OD600 of 0.08. The 
bacterial suspension was supplemented with 0.5% glucose (as a positive control for growth) or 14,15-EET 
(1 µM) and bacterial growth was measured at one-hour intervals for 18 hours.
3.3.4 Cif-mediated 14,15-EET hydrolysis reduced 15-epi LXA4 production and 
disinhibited transepithelial migration   
Since AEC-derived 14,15-EET can trigger neutrophil generation of the pro-resolving 
mediator 15-epi LXA4 [151, 156], we next examined if Cif-mediated hydrolysis of 14,15-
EET impacted 15-epi LXA4 biosynthesis. Neutrophils obtained from healthy donors or CF 
subjects were exposed to 14,15-EET alone or in combination with either Cif-WT or Cif-
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D129S. Following incubation, lipids were extracted from supernatants and quantified by 
ELISA for 15-epi LXA4. As expected, neutrophils generated 15-epi LXA4 when incubated 
with 14,15-EET, and 15-epi LXA4 levels were significantly reduced in the presence of Cif-
WT (Figure 7A). Similar results were also observed for neutrophils from CF donors (Figure 
7B).  
Figure 7. Cif hydrolysis of 14,15-EET reduced 15-epi LXA4 production by healthy and CF neutrophils.  
(A) Generation of 15-epi LXA4 by healthy neutrophil donors in the presence of 14,15-EET (blue symbols) is
reduced in the presence of recombinant Cif-WT (red symbols) but not by the catalytic mutant Cif-D129S (grey
symbols). Freshly isolated human neutrophils from healthy donors (106) were incubated with 14,15-EET (1
µM) in either the presence of Cif-WT or Cif-D129S (1 µM). The reactions were stopped with cold MeOH, lipid
extracted and analyzed for 15-epi LXA4 concentrations by ELISA. * P <0.05, ** P <0.01; one-way ANOVA
with Tukey’s post hoc test; N≥3; Mean. (B) the production of 15-epi LXA4 by CF neutrophil donors in the
presence of 14,15-EET (blue symbols) is reduced in the presence of recombinant Cif-WT (red symbols) but not
by the catalytic mutant Cif-D129S (grey symbols).  * P <0.05, ** P <0.01; Paired one-way ANOVA with
Tukey’s post hoc test.
In a neutrophil-CFBE co-culture model, CFBE cells were treated with TNFα to 
induce the production of 14,15-EET and then incubated with neutrophils. Apical supernatants 
from the neutrophil-CFBE co-culture showed robust production of 15-epi LXA4 following 
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TNFα stimulation. The addition of Cif to the neutrophil-CFBE co-culture substantially 
reduced transcellular generation of 15-epi LXA4 to near baseline levels (Figure 8A). Since 
neutrophils have the capacity to produce both 15-epi LXA4 and LXA4 epimers, we examined 
whether Cif could reduce the biosynthesis of both pro-resolving lipid mediators. TNFα 
induced 14,15-EET did not stimulate transcelluar LXA4 generation in the neutrophil-CFBE 
co-cultures. Therefore, Cif mediated hydrolysis of 14,15-EET had no effect on LXA 
generation in co-culture (Figure 8B). 
Figure 8. Cif mediated 14,15-EET hydrolysis reduced 15-epi LXA4 production but did not have an effect 
on LXA4 generation.  (A) Cif hydrolysis of 14,15-EET suppresses the production of 15-epi LXA4 in CFBE-
neutrophil co-culture. Polarized CFBEs stimulated with TNFα (1 ng/ml) for 24 hours (blue bar) were treated 
apically with Cif-WT (1 µM) for 45 minutes (red bar), prior to the apical addition of 1.5x106 of freshly isolated 
neutrophils for an additional 15 minutes. The apical supernatants from the co-cultures were collected and 
analyzed for 15-epi LXA4 by ELISA. Data are normalized to CFBEs treated with TNFα. * P <0.05, ** P <0.01; 
one-way ANOVA with Tukey’s post hoc test; N≥3; Mean ±SD. (B) Cif hydrolysis of 14,15-EET does not impact 
the production of LXA4 in CFBE-neutrophil co-culture. T he apical supernatants from the co-cultures as described 
above were collected and analyzed for LXA4 by ELISA. Data are normalized to CFBEs treated with TNFα.
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15-epi LXA4 is a potent inhibitor of neutrophil transepithelial migration [187], so we
next modified our co-culture system to examine whether Cif affects neutrophil transepithelial 
migration. Polarized CFBE cell monolayers were grown on the bottom of 3µM pore 
Transwell permeable membrane supports to physiologically model neutrophil transepithelial 
migration in the basolateral-to-apical direction.  The neutrophil chemoattractant IL-8 was 
added in the apical compartment to drive neutrophil migration [204]. Exposure of neutrophils 
to 14,15-EET (100 nM, 45 minutes) or to 15-epi LXA4 (100 nM, 15 minutes) significantly 
decreased transepithelial migration by 74% and 84% respectively (Figure 9). Cif-WT, but 
not Cif-D129S significantly abrogated the inhibition of neutrophil transepithelial migration 
mediated by the addition of 14,15-EET. In addition, Cif-WT had no direct effect on 
migration when added in the presence of 15-epi LXA4. These data demonstrate that Cif-
mediated hydrolysis of 14,15-EET inhibits the generation of 15-epi LXA4, disrupting its 
regulation of neutrophil transepithelial migration in the presence of IL-8. 
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Figure 9.  Cif hydrolysis of 14,15-EET abrogates the reduction of neutrophil transepithelial migration 
mediated by 15-epi LXA4. Freshly isolated human neutrophils (5×105) were calcein-AM loaded and treated 
with either 15-epi LXA4 (light blue bar) in the presence of Cif-WT (light red bar) or 14,15-EET (blue bar) in the 
presence of Cif-WT (red bar) or Cif-D129S (grey bar) for 15-45 minutes, as noted in the methods. The treated 
neutrophils were applied to the basolateral side of polarized CFBEs following the apical addition of the 
chemoattractant IL-8 (black bar, IL-8 positive control; white bar, no IL-8 negative control). After 2 hours, 
calcein-AM fluorescence was measured in the apical compartment to assess neutrophil transepithelial 
migration. Each experimental condition is compared to the migration measured in the positive control condition. 
**** P <0.0001; one-way ANOVA with Tukey’s post-hoc test; N≥4; Mean ±SD. 
3.3.5 Pseudomonas aeruginosa infection in an acute murine pneumonia model reduces 
15-epi lipoxin A4 in bronchioalveolar lavage fluid
To determine if Cif impacts 15-epi LXA4 generation in vivo, we utilized an acute P. 
aeruginosa mouse pneumonia model [205]. P. aeruginosa strain PA14 or a PA14:cif-D129S 
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knock-in mutant were administered by oropharyngeal aspiration, and bronchoalveolar lavage 
fluid (BALF) was harvested 24 hours post-infection. Mice exposed to PA14 had BALF levels 
of 15-epi LXA4 that were significantly lower than the PA14::Cif-D129S group and much 
closer to the mock-infected mice (Figure 10). Thus, during an acute infection in vivo, the 
presence of a catalytically active Cif enables PA14 P. aeruginosa to disrupt production of 
15-epi LXA4.
Figure 10. Oropharyngeal aspiration of a Cif producing P. aeruginosa strain reduces 15-epi LXA4  in 
bronchial alveolar lavage fluid in a murine pneumonia model.  (A) Experimental design for murine 
pneumonia model. (B) In a acute pneumonia model, 15-epi LXA4 concentrations are significantly reduced in 
murine BALF when infected with PA14 compared to the Cif mutant strain PA14::Cif-D129S. Adult male 
C57Bl/6J mice were inoculated with 40 μl (1 × 106 CFU) of P. aeruginosa PA14 or isogenic PA14:Cif-D129S 
via oropharyngeal aspiration. BALF was collected in PBS 24hpi and immediately methanol trapped. The 
samples were solid-phase lipid extracted and analyzed for 15-epi LXA4. ** P < 0.001, *** P < 0.0001; one-
way ANOVA.
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3.3.6 Cif expression in CF patients is widespread and correlates with elevated IL-8, loss 
of 15-epi LXA4 and reduced pulmonary function 
Based on our in vitro preclinical data and in vivo studies in the mouse pneumonia model, we 
hypothesized that Cif levels in patients with CF would be positively correlated with lung 
inflammation and inversely correlated with BALF levels of 15-epi LXA4 and with several 
measures of lung function. To test these hypotheses, we obtained BALF from a random 
cross-sectional cohort of pediatric CF subjects who had undergone bronchoscopy (Table 1). 
Using newly developed Cif-specific antisera (Figure 11) we quantified Cif abundance in 
BALF samples that tested positive for the presence of P. aeruginosa lipopolysaccharide.  
Table 1. Demographics of the patient cohort from which CF bronchoalveolar lavage fluid was obtained 
Patient Age Gender Binned Cif group 
1 13 F High 
2 16 M Low 
3 18 F Low 
4 17 F Low 
5 4 M High 
6 13 F Low 
7 11 M High 
8 17 F Low 
9 13 F High 
10 7 F High 
11 13 M Low 
12 12 F Low 
13 16 F Low 
14 14 M High 
15 16 F Low 
16 11 F High 
17 17 F Low 
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Figure 11. Cif is detected in bronchoalveolar lavage fluid from CF patients.  (A) Cif antisera is specific for 
Cif protein in CF patient BALF. CF patient BALF (6µg/lane) was separated by SDS-PAGE and anti-Cif 
polyclonal rabbit serum was used for detection by Western blot. Samples were tested for P. aeruginosa 
polysaccharide and were categorized as P. aeruginosa positive (With Pa) or negative (No Pa). Recombinant Cif-
WT protein is shown as a positive control. Arrow denotes the molecular weight of Cif. (B) Cif protein is 
detected in CF patient BALF. Bronchial alveolar lavage fluid was obtained from CF pediatric patients who 
received bronchoscopy. N=17. A standard curve was generated using recombinant Cif-WT protein (top panel). 
BALF for each study subject (6µg/lane) was separated by SDS-PAGE and Cif protein was detected by Western 
blot. Cif was quantified in each BALF sample by densitometry utilizing a standard curve of known amounts of 
recombinant Cif protein. Cif protein concentrations are reported in Figure 13. Patient ID number and the 
associated classification as low Cif (L) or high Cif (H) are shown above and below each lane, respectively.
We also quantified the levels of IL-8 and 15-epi-LXA4 in these samples by ELISA. A 
Pearson cross-correlation matrix of available data demonstrated patterns clearly consistent 
with our predictions (Figure 12). Pulmonary function tests (solid outline) showed strong 
positive correlations with each other, consistent with CF airway disease. 15-epi LXA4 levels 
positively correlated with lung function (dashed outline), consistent with the idea that pro-
resolution signals are protective against inflammatory lung damage in CF. As predicted, Cif 
inversely correlated with both 15-epi LXA4 and pulmonary function measures (dotted 
outline), and IL-8 inversely correlated with 15-epi LXA4 and positively with Cif (red line).  
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Figure 12. Cif levels in CF patient BALF positively correlated with lung inflammation and 
inversely correlated with 15-epi LXA4 and with several measures of lung function.  Elevated levels of Cif 
in CF patient bronchial lavage fluid result in lower 15-epi LXA4 and higher IL-8 concentrations and 
worsening pulmonary function. A visualization of a Pearson correlation matrix depicts positive 
correlations in blue and negative correlations in red. Color intensity and the size of the circle are 
proportional to the correlation coefficients. Below the correlogram, the scale shows the correlation coefficients 
and the corresponding colors.   
To investigate these patterns in more detail, we divided patients into “Cif low” and 
“Cif high” groups (Figure 13A), using 10 ng Cif per mg of total protein to delineate groups. 
Individual analyses confirmed significantly reduced levels of 15-epi LXA4 and poor lung 
function and pulmonary obstruction as measured by FEV1/FVC (Figure 13B, and E). 
Furthermore, IL-8 an important inflammatory chemokine was elevated in patients with 
higher levels of Cif, demonstrating that Cif abundance correlated with worse pulmonary 
inflammation (Figure 13D). Lastly, in the patient cohort, IL-8 and 15-epi LXA4 are strongly 
inversely correlated (Fig. 13C). Thus, among subjects with P. aeruginosa infections, Cif 
levels are associated with worse obstructive lung disease.   
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Figure 13. Elevated levels of Cif in CF patient BALF resulted in less 15-epi LXA4 levels, higher 
IL-8 concentrations and more pulmonary obstruction.  (A) Cif expression in CF patient BALF was 
determined by Western blot analysis, and binned into “low” and “high” categories. (B) 15-epi LXA4 
concentrations are significantly reduced in CF patients with elevated levels of Cif. CF BALF samples were 
lipid extracted and analyzed for 15-epi LXA4 concentrations by ELISA. * P < 0.05 Wilcoxon Rank-Sum Test. 
(C) Increased IL-8 concentrations strongly correlate with lower 15-epi LXA4 concentrations in CF patient
BALF. ** P = 0.0016, Pearson correlation. (D) CF patients with elevated Cif have increased IL-8
concentrations in the airways. IL-8 concentrations in CF BALF were determined by sandwich ELISA and
normalized to total protein in each sample. P = 0.055 Wilcoxon Rank-Sum Test.  (E) CF patients with high
Cif have worse lung obstruction. Patient FEV1/FVC ratio was measured at time of bronchoscopy, stratified
by high or low Cif groups. * P <0.05, Wilcoxon Rank-Sum Test.
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3.4 DISSCUSSION 
A major hallmark of the disease cystic fibrosis is vigorous and persistent pulmonary 
inflammation, which damages host lung tissue, eventually causing respiratory failure and 
death. Chronic P. aeruginosa infections often accompany robust airway inflammatory 
processes, provoking continuous immune cell infiltration into the lung. In the current study, 
we identified the epithelial-derived eicosanoid 14,15-EET as an endogenous substrate for the 
P. aeruginosa virulence factor Cif. We also showed that the Cif-mediated reduction of 14,15-
EET disrupted paracrine signaling to neutrophils to produce 15-epi LXA4, blocking its pro-
resolving functions. 
Figure 14. Summary Figure 
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Consistent with the Cif-mediated effect of blocking the generation of pro-resolving 
mediators, we demonstrated that higher Cif levels in the bronchoalveolar lavage fluid of CF 
patients correlated with reduced 15-epi LXA4, increased inflammatory marker IL-8 and 
reduced pulmonary function. Taken together, our results provide evidence for a novel role of 
the bacterial epoxide hydrolase Cif in obstructing normal resolution pathways in the airway 
and promoting pulmonary inflammation in CF patients colonized with P. aeruginosa. 
In contrast to the pro-inflammatory effects of Cif, several pathogens manipulate lipid 
mediators to suppress the immune response and evade detection. Mycobacterium 
tuberculosis and Toxoplasma gondii both enhance the generation of lipoxins [209, 210], 
while the fungal pathogen Candida albicans synthesizes resolvin E1 [184]. Mycobacterium 
tuberculosis can also inhibit the formation of the pro-inflammatory lipid LTB4, further 
shifting the host lipid environment towards an anti-inflammatory state [211]. P. aeruginosa 
produces the 15-lipoxygenase LoxA [176, 212], as well as the phospholipase ExoU [170], 
both of which can potentially generate anti-inflammatory signals. However, unlike many 
airway pathogens, P. aeruginosa survives in a hyper-inflammatory environment, particularly 
in the context of chronic lung disease [8]. As a result, P. aeruginosa may be uniquely poised 
to exploit both pro- and anti-inflammatory strategies to thwart host defense mechanisms. 
14,15-EET is the first host substrate identified for P. aeruginosa Cif. Previous 
crystallization studies identified Cif as a member of the α/β-hydrolase family of proteins, 
with epoxide hydrolase activity focused on small, monosubstituted substrates [191]. Thus, it 
was surprising to discover that Cif could accommodate the extended carbon chain of an 
eicosanoid such as 14,15-EET.  Our crystal structure revealed an unexpected rearrangement 
of specific residues that define the boundaries of the active site. Small-molecule inhibitors 
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were recently reported to drive conformational changes in an epoxide hydrolase active site 
[213], but our study represents the first example of a substrate-induced fit in this class of 
enzymes. Furthermore, while our work shows that Cif cannot hydrolyze the other EET 
regioisomers, its active-site flexibility may enable it to hydrolyze other members of the broad 
network of regulatory lipids [214].  
Among its multiple anti-inflammatory functions [215, 216], 14,15-EET plays a 
particularly critical role as a paracrine stimulus for the production of the pro-resolving lipid 
15-epi LXA4 by neutrophils [151]. In addition to enzymatically targeting 14,15-EET, our
study also demonstrated that Cif indirectly reduced levels of the pro-resolving lipid mediator 
15-epi LXA4. Our data provide the first evidence that the capacity to generate 15-epi LXA4 is
fundamentally intact in the context of CF, yet susceptible to Cif-mediated reductions when P. 
aeruginosa is present in the CF airway. Specifically, the production of 14,15-EET and the 
associated modulation of neutrophil behavior were both observed with primary cells derived 
from CF patients. Consistent with this proposal, elevated levels of Cif in CF patient BALF 
correlated with reduced concentrations of 15-epi LXA4, increased levels of the inflammatory 
cytokine IL-8, and worsened pulmonary function. Our study suggests that by inhibiting 
normal host resolution programs, the secreted P. aeruginosa virulence factor Cif contributes 
to the characteristic hyper-inflammatory environment of the CF airway.  
These results have important implications for our understanding of CF disease 
pathogenesis. The targeting of the pro-resolution 14,15-EET/15-epi LXA4 axis represents an 
unexpected bacterial virulence strategy. As is demonstrated by decades-long chronic 
infections in the inflamed lungs of CF patients, P. aeruginosa thrives in a hyper-
inflammatory environment [217]. Here we show that a majority of pulmonary clinical 
59 
isolates from CF patient express Cif, implying this conserved virulence mechanism may be 
vital during chronic pulmonary infection. Since our data demonstrates that Cif enables P. 
aeruginosa to manipulate the host inflammatory environment, it may play an important role 
in defining the nature of these on-going infections, which ultimately lead to lung tissue 
damage and respiratory failure. Functional Cif homologs have been identified in other airway 
pathogens, including Acinetobacter nosocomialis and Burkholderia cepacia [97, 101]. As a 
result, these bacterial epoxide hydrolases may represent a new class of therapeutic targets in 
CF and other airway diseases in which hyper-inflammatory responses accelerate tissue 
damage. 
Our observations may also suggest novel therapeutic approaches, as increased Cif 
levels correlated with more severe obstructive lung disease, as measured by FEV1/FVC 
ratios, in CF patients. As increasing FEV1/FVC ratio remains a key therapeutic objective of 
clinical therapy, one strategy may be direct replacement of the absent lipoxin. Multiple 
studies have demonstrated that exogenous administration of specialized pro-resolving 
mediators improve morbidity and mortality outcomes following infection [167]. In particular, 
the administration of a LXA4 analog in mice challenged intratracheally with P. aeruginosa 
led to reduced neutrophil infiltration, weight loss, and bacterial burden, resulting in overall 
lessening of disease severity [54]. An alternative strategy may be to inhibit Cif activity with a 
targeted small-molecule approach [96, 218]. Our observations a murine acute pneumonia 
model indicate that eliminating Cif epoxide hydrolase activity would in fact elevate 15-epi 
LXA4 levels in the airway during P. aeruginosa infection. In addition to blocking the 
enzymatic degradation of lipid mediators, inhibitors would also block the ability of Cif to 
subvert rescue of CFTR by recently approved clinical correctors [219]. Finally, since Cif 
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represents a key link between chronic infections and the damaging, hyper-inflammatory 
environment present in the CF airway, it may serve as a valuable biomarker of airway disease 
and treatment options in CF. 
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4.1 INTRODUCTION 
Respiratory viral infections are associated with the increased acquisition of secondary 
bacterial superinfections resulting in greater immunopathology [220-222]. This association is 
of great research interest, especially in the area of CF, where respiratory viral infections are 
linked to pulmonary exacerbation and enhanced bacterial acquisition. Respiratory viral 
infections are associated with disease progression in CF, promoting early respiratory tract 
morbidity and poor lung function [125, 223, 224]. Clinical studies in CF patients also link 
RSV infections to the development of P. aeruginosa chronic infections [116, 117, 225]. This 
clinical observation is supported in scientific studies as mice co-infected with RSV and P. 
aeruginosa have significantly higher colony forming units of P. aeruginosa in the lung 
homogenates compared to bacterial infection alone [226, 227]. Although numerous reports 
demonstrate an epidemiological link between viral infections, increased bacterial load and 
pulmonary exacerbation in CF patients, the molecular mechanisms that govern these 
complicated biologic interactions is unclear and need further examination. 
The airway epithelium is a critical component of the innate immune system, 
providing the first line of defense against respiratory pathogens [7, 8]. AECs respond to viral 
infections by producing interferon (IFN), which signals in an autocrine and paracrine manner 
to induce antiviral cellular activities [228]. Both type I (IFN α/β) and type III (IFN-λ) 
interferon’s can be secreted by the epithelium, however, IFN-λ is expressed in greater 
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abundance [229]. Moreover, the receptor for IFN-λ receptor is restricted to mucosal sites and 
primarily expressed by epithelial cells, dendritic cells and neutrophils [230-233], whereas 
IFN α/β receptors are universally expressed on all nucleated cells [228]. IFN-λ is structurally 
related to the IL-10 cytokine family and signals through a heterodimer composed of the 
unique IL-28αR chain and the shared IL-10R chain [234, 235]. IFN-λ signaling results in a 
variety of antiviral activities included the degradation of RNA, interference with vial 
assembly and release as well as up-regulation of MHC class I antigen expression [228]. 
Multiple studies have linked IFN α/β to promoting secondary bacterial infections [236-238]. 
However, few studies have determined whether IFN-λ, whose receptor mainly is 
concentrated at mucosal surfaces, contributes to detrimental secondary bacterial infections. 
As it is well known that P. aeruginosa thrives in biofilm communities in CF airway, we 
investigated if the appropriate production and signaling of IFN-λ following RSV infection of 
AECs enhanced bacterial biofilm growth.  
The inflammation generated by the host is a significant factor in RSV disease 
pathology. Robust immune cell infiltration, epithelial cell sloughing and increased mucus 
secretion is characteristic of RSV respiratory infection, resulting in bronchiolitis and airway 
obstruction [239]. With few available effective treatment options and failure to develop 
natural immunity, perhaps enhancing endogenous pathways that resolve inflammation could 
be modern strategy to curb damaging RSV pathology.  
Specialized pro-resolving lipid mediators (SPM) are key signaling molecules that 
down-regulate inflammatory pathways and promote the return to tissue homeostasis [186].  
Although well recognized for their role in sterile and allergic inflammation, the contributions 
of SPMs in restraining inflammation from infectious insults is recently becoming more 
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appreciated. One study demonstrated the importance of both 5-lipoxygenase and 15-
lipoxygenase activities in macrophage, for promoting the resolution of RSV induced 
inflammation [240]. This study focused on RSV induced pathology and macrophage 
responses to RSV did not show viral burden in their murine model. AECs are the primary 
cell type infected by RSV. Therefore, in this study we assessed SPM treatment on viral 
burden and the host response to the infection in AECs.  
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4.2 MATERIALS AND METHODS 
Epithelial cell culture. Primary human CF bronchial epithelial cells (CF HBE) were 
obtained from explanted CF patient lungs and cultured by the University of Pittsburgh 
Airway Cell and Tissue Core under an Institutional Review Board approved protocol at the 
University of Pittsburgh (IRB# 11070367).  CF HBE were seeded on 6.5 mm transwell 
inserts with a 0.4 mm pore size (Corning Life Sciences) at 2.5×105 cells per filter for 4-6 
weeks at air–liquid interface at 37°C with 5% CO2 until they were polarized and 
differentiated [241]. CFBE41o- cells, an immortalized human bronchial epithelial cell line 
derived from a ΔF508 homozygous cystic fibrosis patient, and the WT CFTR complemented 
CFBE41o- cell line (CFBE41o- wt) were generously provided by Dr. J.P. Clancy. The cells 
were cultured in minimum essential media (MEM, Gibco) supplemented with 2 mM L-
Glutamine (Corning), 5 U/mL Penicillin and 5 μg/mL Streptomycin (Sigma), 0.5 μg/mL 
Plasmocin prophylactic (InvivoGen), and 10% Fetal Bovine Serum (FBS, Gemini Bio-
Products). CFBE41o- or CFBE41o- wt cells were seeded onto collagen-coated 6.5 mm 
transwell inserts at 7×104  cells per filter and grown at an air-liquid interface at 37°C and 5% 
CO2 for 8 – 10 days to allow for cell polarization.  
RSV and P. aeruginosa infections. Respiratory Syncytial Virus (RSV) line A2 strain was 
propagated in NY3.2 cells, immortalized murine fibroblast cells from a STAT1-/- mouse 
[242]. For virus infection, primary CF HBEs or the cell lines CBFE41o- or CFBE41o- wt 
were washed with MEM supplemented with 2 mM L-Glutamine and the basolateral media 
was replaced with fresh media without antibiotics.  The cells were apically inoculated with 
RSV diluted in MEM supplemented with 2 mM L-Glutamine to an MOI of 0.1 or 1. The 
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cells were incubated for 7 hours at 37˚C before the apical media was removed to allow the 
airway cells to retain their polarity. RSV infections then were allowed to proceed for 72 
hours prior to inoculation with P. aeruginosa.  
mRNA Expression. Prior to RNA isolation, the cells were washed apically and basolaterally 
twice with PBS (Gibco) supplemented with 0.1 mM Calcium Chloride (Fisher Scientific) and 
1 mM Magnesium Chloride (Fisher Scientific). Total RNA was extracted using RNeasy Mini 
Kit (Qiagen) and cDNA was synthesized with iScript cDNA Synthesis Kit (Bio-Rad). 
Quantitative Real-Time PCR by iQ SYBR Green Supermix (Bio-Rad) was performed using a 
StepOne System (ThermoFisher Scientific) to evaluate viral infection and interferon 
signaling gene expression. Data were normalized to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and the fold change of target mRNA expression was determined 
by the 2-ΔΔCT method with control cells as calibrators. The following primers were used  
GAPDH 5'-CGACCACTTTGTCAAGCTCA-3’(F),  
5'-AGGGGAGATTCAGTGTGGTG-3’(R) 
RSV 5’-GCTCTTAGCAAAGTCAAGTTGAATGA-3’ (F) 
5’-TGCTCCGTTGGATGGTGTATT-3’ (R) 
IFNL1 5'-CGCCTTGGAAGAGTCACTCA-3’ (F) 
5'-GAAGCCTCAGGTCCCAATTC-3’ (R) 
IL-8 5'- CTGGCCGTGGCTCTCTTG-3’ (F) 
5'- CCTTGGCAAAACTGCACCTT-3’ (R) 
67 
CCL20   5'- TATATTGTGCGTCTCCTCAG-3’ (F) 
 5'- GCTATGTCCAATTCCATTCC-3’ (R) 
ALX/FPR2  5'- AGTCTGCTGGCTACACTGTTC-3’ (F) 
 5'- TGGTAATGTGGCCGTGAAGA-3’ (R) 
Biotic Biofilm Assay. Following 72 hours of RSV infection, AECs were inoculated apically 
with P. aeruginosa strain PAO1. Overnight cultures of PAO1 grown at 37˚C in LB were 
washed and diluted in MEM supplemented with 2mM glutamine. The AECs were inoculated 
with ~7x106 bacteria, corresponding to a multiplicity of infection of 25. After 1 hour of 
bacterial attachment, unattached bacteria were removed and the apical media was replaced 
with MEM containing 2mM glutamine and 0.4% L-Arginine (Sigma-Aldrich). After an 
additional 5 hour incubation, apical media was removed and cells were washed with MEM 
apically and basolaterally to remove unattached bacteria. The attached biofilms were then 
disrupted with MEM containing 0.1% Triton X-100 (Bio-Rad). Bacteria were serially diluted 
and plated on LB agar to determine colony-forming units (CFU).  
IFN-λ ELISA. To measure the apical secretion of IFN-λ following 72 hours of RSV 
infection, MEM supplemented with 2mM glutamine was added during the final 18 hours to 
the apical compartment of the CFBE cells. The apical secretions were collected and frozen at 
-80°C until analysis. IFN-λ (IL-29/IL-28B) concentrations was measured with the human IL-
29/IL-28B DuoSet ELISA (R&D Systems) as per manufacturer’s instructions. 
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IFN-λ signaling and biofilm growth. Following RSV for 72 hours and CFBE cells were 
treated with 10 µg/mL IL-10Rβ neutralizing antibody (IL-10Rβ Ab; R&D systems) for the 
final 12 hr of infection. The CFBE cells were inoculated with P. aeruginosa and biotic 
biofilm growth was measured by CFU/ml.  For siRNA experiments CFBE were transfected 
with scrambled siNeg or siRNA targeting IL-28Rα (siIL28Rα) prior to IFN-λ treatment and 
biotic biofilm assay. Abiotic biofilm growth in the presence of IFN-λ (200 ng/mL) was 
measured following 24 hour growth in 96-well microtiter plate. Biofilm growth was 
measured as absorbance at A550 following crystal violet staining as previously described 
[243]. 
15-epi lipoxin A4 treatment of RSV infected AECs. 15-epi LXA4 (Calbiochem) was
diluted in MEM supplemented with 2 mM L-Glutamine to a working concentration of 2µM 
as determined by OD302. The 15-epi LXA4 was further diluted to a final concentration of 
100nM by direct addition to the apical and basolateral media previously added to the CFBE 
cells. 15-epi LXA4 was added either at the same time as RSV infection (T=0), 24 or 48 hours 
post RSV infection.  
Plaque assay. NY3.2 cells were seeded at 4×105 cells/well in 24-well plates (Corning) that 
were coated with polyethylenimine (Sigma). To measure infectious RSV particles released 
from CFBE cells, MEM supplemented with 2mM glutamine was added during the final 18 
hours to the apical compartment of the CFBE cells. The apical secretions were collected and 
serially diluted in DH125 media. NY3.2 cells were inoculated with the diluted apical 
secretions for 2 hours at 37˚C prior to the addition of a methyl cellulose (Sigma-
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Aldrich)/polyethylene glycol overlay (Fisher Scientific). After 48 hours incubation, the 
NY3.2 cells were fixed in 10% Buffered Formalin Phosphate (Fisher Scientific). Anti-RSV 
antibody (Meridian Life Science, Inc.), anti-Goat-AP conjugated antibody (Santa Cruz 
Biotechnology) and SIGMAFAST BCIP/NBT (Sigma) were added in sequence to detect 
plaque-forming units (PFU).  
Statistics. Experimental differences for in vitro assays were evaluated for statistical 
significance using GraphPad 6.0 Software.  All in vitro data are shown as Mean ± SD. P < 
0.05 was considered statistically significant.  
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4.3 RESULTS 
4.3.1 Respiratory syncytial virus infection enhances P. aeruginosa biofilm growth on CF 
airway epithelial cells 
To model P. aeruginosa biotic biofilm growth in the CF airway, we utilized an in-vitro co-
culture system with well-differentiated polarized human AECs grown at an air-liquid 
interface cells [244]. To determine if we could model the clinical observation that viral 
infection enhances P. aeruginosa colonization, we first tested if viral infection in primary CF 
bronchial epithelial cells (CF HBE) altered biofilm growth using a static biotic biofilm co-
culture system (Figure 15A). Preceding infection of RSV (MOI=1) for 72 hours in two CF 
HBE codes resulted a significant increase in P. aeruginosa biofilm growth compared to no 
viral infection control (Figure 15B).   
In order to further examine this observation and explore the potential mechanism 
mediating this increase in biofilm formation, we utilized the genetically tractable 
immortalized CF bronchial epithelial cell line (CBFE), which we infected with RSV for 72 
hours prior to inoculation with P. aeruginosa (Figure 15C). We found that RSV infection 
with a MOI=1 significantly increased biofilm formation as seen previously with the primary 
CF HBE codes. Previous studies reported that P. aeruginosa biofilm growth is increased on 
airway epithelial cells with the CF genotype, as compared to non-CF cells [102], therefore we 
tested if CFTR activity was facilitating the virus mediated biofilm growth. We infected a 
CFBE cells complemented with wt CFTR and found that the presence of a functional CFTR  
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did not abrogate virus induced biofilm production (Figure 15D). These results demonstrate 
that preceding RSV infection increases the production of P. aeruginosa biofilm on CF AECs 
and this effect is independent of CFTR function.  
Figure 15. RSV co-infection induces robust P. aeruginosa biofilm growth on CF AECs. (A) Experimental 
design for assessing biotic P. aeruginosa biofilm grown on AECs. (B) RSV infection promotes P. aeruginosa 
biofilms grown on primary CF HBE cells from two individuals with CF. CF HBE cells were infected with RSV 
(MOI=1) for 72 hours prior to apical inoculation with PA01 (MOI=25). Following 6 hour incubation at 37˚C 
biofilms disrupted with 0.01% Triton and quantified by CFU/ml. * P < 0.05; two-way ANOVA with Sidak’s 
post-hoc test; N=3 for each code; Mean ±SD (C) CFBE or (D) CFBE + wt CFTR were infected with RSV at a 
MOI = 0.1 or 1 for 72 hours prior to apical inoculation with PA01 (MOI=25). Following 6 hour incubation at 
37˚C biofilm were disrupted with 0.01% Triton and quantified by CFU/ml * P < 0.05, ** P < 0.01; one-way 
ANOVA with Tukey’s post-hoc test compared to no virus control; N=3; Mean ±SD.
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4.3.2. Antiviral IFN-λ enhances P. aeruginosa biotic biofilm growth 
AECs orchestrate innate host defense against respiratory viral infections by secreting 
antiviral interferons (IFN). Therefore, we sought to determine if the increase in bacterial 
biofilm following RSV infection was due the secretion of IFN-λ. We therefore measured the 
production of IFN-λ in CFBE cells upon RSV infection over time to determine if there was a 
temporal relationship between IFN-λ secretion and P. aeruginosa biofilm production. We 
observed in our model that the greatest P. aeruginosa biofilm production occurred 72 hours 
post RSV infection (Figure 16A). Interestingly this time point corresponded with peak apical 
secretion and mRNA expression of IFN-λ1 (IL-29) during the course of RSV infection 
(Figure 16B and 16C). We also observed increased IFN-λ1 expression levels in primary CF 
HBE cells at 72 hours post RSV infection (Figure 16D). These results indicate a temporal 
association between CFBE apical IFN-λ secretion and P. aeruginosa biofilm induction.  
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Figure 16. The temporal production of IFN-λ following RSV infection correlates with enhanced 
P. aeruginosa biofilm growth. (A) CFBE cells were infected with RSV at a MO=1 for the time points indicated,
prior to apical inoculation with PA01 and biofilm production was quantified by CFU/ml ** P < 0.01; one-way
ANOVA with Tukey’s post-hoc test; N=3; Mean ±SD (B) Apical secretion of IFN-λ1/3 (IL-29/28B) by ELISA
from CFBE cells infected with RSV (MOI=1) for the indicated number of hours (hpi). *** P < 0.001; one-way
ANOVA with Tukey’s post-hoc test; N=3; Mean ±SD (C) IFN-λ1 gene expression in CFBE cells infected with
RSV (MOI=1) measured by qPCR over the indicated time points, normalized for GAPDH and presented as fold
change from the uninfected control. N=1 (D) IFN-λ1 gene expression in two primary CF HBE codes infected
with RSV for either 48 hours or 72 hours (MOI=1) measured by qPCR, normalized for GAPDH and presented
as fold change from the uninfected control.
We next sought to  determine if IFN-λ signaling was required for virus stimulated P. 
aeruginosa biofilm growth. We treated CFBE cells with neutralizing IFN-λR antibody prior 
to P. aeruginosa inoculation and observed a decrease in the virus enhanced P. aeruginosa 
biofilm growth (Figure 17A).  These results indicated that IFN-λR signaling was important 
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for mediating viral enhanced bacterial biofilm growth. We then tested if direct addition of 
IFN-λ1 to CFBE cells was sufficient to induce P. aeruginosa biotic biofilm growth. IFN-λ1 
was added apically to CFBE cells for 14 hours prior to inoculation with P. aeruginosa. 
(Figure 17B). IFN-λ1 treatment was sufficient to promote P. aeruginosa biofilm growth on 
CFBE cells in a dose-dependent manner. Furthermore, when we inhibited IFN signaling 
through using RNAi-mediated IL-28Rα knockdown prior to IFN-λ treatment we also saw a 
decrease in biofilm growth (Figure 17C). Together, these results show that host anti-viral 
IFN-λ responses promote P. aeruginosa biofilm growth on AECs.  
Lastly we tested if IFN-λ interacted directly with P. aeruginosa to enhance biofilm 
growth. Bacteria were grown in a 96-well microtiter plate in the presence of IFN-λ 
(200ng/ml) and biofilm were stained with crystal violet and measured by OD550 (Figure 
17D). The presence of IFN-λ did not alter biofilm growth, which indicates that the bacterium 
does not directly utilize IFN-λ for biofilm growth.  
75 
Figure 17. IFN-λ signaling is required and sufficient to mediate virus-stimulated P. aeruginosa biofilm 
growth.  (A) CFBE cells were infected with RSV 72 hours and treated with IL-10Rβ–neutralizing antibody 
(gray bars) or were left untreated (white bars) * P < 0.05; N ≥ 3; Mean ± SD; (B) CFBE cells were 
treated IFN-λ1 with the indicated concentrations for 14 hours prior to apical inoculation with P. aeruginosa. 
Biofilms were quantified by CFU/ml. * P < 0.05; one-way ANOVA with Tukey’s post-hoc test; N=3; Mean ±SD. 
(C) AECs were transfected with scrambled siRNA (siNeg white bars) or siRNA targeting IL-28Rα (siIL28Rα
grey bars) prior to IFN-λ1 treatment and biofilm assay * P < 0.05; N ≥ 3; Mean ± SD. (D) P. aeruginosa
biofilms were grown in a 96-well microtiter biofilm assay in the presence or absence of IFN-λ (200 ng/mL)
diluted in MEM for 24 hours. Biofilm growth was measured as absorbance at OD550 following crystal violet
staining. N = 3; Mean ± SD.
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4.3.3 15-epi LXA4 treatment reduces RSV burden 
Recent studies demonstrate that SPM treatment can reduce viral replication and pathology 
associated with infection [107, 245]. Other reports have demonstrated that AECs express the 
lipoxin receptor FPR2/ALX, [246, 247]. To confirm that our CFBE cells express FPR2/ALX 
we measured receptor expression by qPCR. We found that CFBE cells express elevated 
FRP2/ALX transcripts compared to A549 cell expression, which have been shown to not 
express the receptor (Figure 18A). Since CFBE cells expressed FPR/ALX, we decided to 
investigate if 15-epi LXA4 treatment during RSV infection could alleviate viral burden in 
infected epithelium. CFBE cells were infected with RSV (MOI=1) and treated with 15-epi 
LXA4 at various time points over the course of infection  (Figure 18B). Following 72 hours 
of RSV infection, CFBE cells were harvested and viral transcripts were measured by qPCR 
and infectious viral particles released in the apical secretions were quantified by plaque 
assay. 15-epi LXA4 treatment done in parallel at the start of RSV infection (T=0) had no 
significant effect on either viral transcript production or plaque forming units (PFU) at 72 
hpi. However, treating CFBE cells with 15-epi LXA4 either 24 or 48 hours into viral 
infection resulted in significantly less viral transcript and PFU (Figure 18C and 18D). 
Interestingly, we observed that CFBE cells begin to ramp up inflammatory processes 48 
hours following RSV infection, as seen by the increase in IL-8 and CCL20 by qPCR (Figure 
18E and F).  These results suggest that treatment of 15-epi LXA4 can reduce viral burden but 
only if administered to AECs after the inflammatory processes induced by the viral infection 
have commenced. 
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Figure 18. Viral burden is reduced upon 15-epi LXA4 treatment in CFBE cells. (A) ALX/FPR2 expression 
measured by qPCR in untreated CFBE and A549 cells. (B) Experimental design for 15-epi LXA4 treatment of 
RSV (MOI=1) infected CFBE cells. (C) RSV gene expression measured by qPCR in CFBE cells infected with 
RSV control (black bar) or with 100nM treatment of 15-epi LXA4 over the indicated time points during 
infection (grey bars).  Data normalized for GAPDH and presented as fold change from the
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uninfected control; N=2; Mean ±SD. (D) The apical release of infectious RSV particles quantitated by plaque 
assay. RSV control (black hashed bar) or with 100nM treatment of 15-epi LXA4 over the indicated time points 
during infection (grey bars); N=2; Mean ±SD. (E) IL-8 and (F) CCL20 gene expression measured by qPCR in 
CFBE cells infected with RSV control at the time points indicated. N=3; Mean ±SD. 
4.3.4 15-epi LXA4 treatment during RSV infection significantly reduces IFN-λ secretion 
by airway epithelial cells and lessens P. aeruginosa biofilm production  
The observation that 15-epi LXA4 treatment 48 hours post-infection reduced RSV viral 
burden suggested that SPM treatment was enhancing IFN-λ production, thereby accelerating 
epithelial control of the infection. Interestingly, we found the inverse; IFN-λ secretion was 
significantly decreased following 15-epi LXA4 treatment at both 24 or 48 hours post 
infection (Figure 19A). This data indicates IFN-λ responses are attenuated in a manner that 
correlates with reduction in viral load, suggesting that 15-epi LXA4 treatment is directly 
targeting virus replication rather than mediating the host response following RSV infection.  
Given our previous observation that apical IFN-λ signaling enhances P. aeruginosa 
biofilm production, we decided to test if 15-epi LXA4 treatment could reduce both viral and 
bacterial burden during co-infection (Figure 19B). 15-epi LXA4 treatment either 24 or 48 
hours after RSV infection resulted in a modest reduction in subsequent P. aeruginosa biofilm 
growth. These results are consistent with the conclusion that treating AECs with 15-epi 
LXA4 during viral infection reduces IFN-λ secretion and lessens both viral and bacterial 
burden.  
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Figure 19. 15-epi LXA4 treatment significantly reduces IFN-λ secretion and blunts virally enhanced 
P. aeruginosa biofim formation. (A) Secretion of IFN-λ (IL-29/28B) was measured by ELISA from
untreated CFBE cells (white bar) or CFBE cells infected with RSV (black bar) in the presence of 15-epi
LXA4 over the indicated time points during infection (dark grey bars). Uninfected CFBE cells were treated
with 15-epi LXA4 in parallel (light grey bars). * P < 0.05; compared to RSV infection control, one-way
ANOVA with Tukey’s post-hoc test; N=3; Mean ±SD. (B) CFBE cells were infected with RSV for 72 hours
and treated with 15-epi LXA4 over the indicated time points during infection prior to apical inoculation with
PA01 (MOI=25). Following a 6 hour incubation at 37˚C biofilms were disrupted with 0.01% Triton and
quantified by CFU/ml. Data expressed as percent biofilm induction following RSV infection compared to
uninfected control; N=1 done in replicate; Mean ±SD
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4.4 DISCUSSION 
Clinical observations have linked respiratory viral infection in CF with pulmonary 
exacerbations and enhanced P. aeruginosa chronic colonization. In this study, we 
demonstrate that RSV infection in primary CF HBE or immortalized CFBE cells promotes 
enhanced P. aeruginosa biofilm growth. We show this interaction is independent of 
functional CFTR activity and instead is due to host antiviral responses. We observed a 
temporal association between peak IFN-λ secretion and elevated P. aeruginosa biofilm 
growth. Interestingly, the direct addition of IFN-λ to uninfected cells recapitulated the 
increase in bacterial biofilm growth, demonstrating that P. aeruginosa is able to take 
advantage of the antiviral environment in the airway lumen. Thus, our study demonstrates 
that anti-viral IFN-λ responses to RSV infection in the airway promote secondary P. 
aeruginosa infection and biofilm growth.   
 Although the antiviral activities of IFN are well appreciated, recent viral-bacterial 
co-infection murine studies reveal that IFN responses have unfavorable consequences on 
secondary bacterial infections [248]. For example, in acute murine models of influenza or 
LCMV, IFN-α/β responses to viral infection impaired control of bacterial load in the airways 
[236-238]. More recently, IFN-λ signaling has also been shown to be detrimental to P. 
aeruginosa infections, as the bacterium was cleared more efficiently in mice that could not 
respond to IFN-λ [249].  Our data extend these findings and demonstrate that IFN-λ 
production by human AECs promotes P. aeruginosa biotic biofilm growth and chronic 
infections. Mucosal IFN-α/β responses have been shown to reduce both antimicrobial peptide 
release and IL-17 responses, both important for controlling extracellular bacterial infections 
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at the mucosa [238]. Others studies demonstrated that IFN target gene effector functions 
promote bacterial replication, suggesting that some pathogens have evolved to subvert and 
even benefit from the interferon response in host cells [250]. As IFN-λ receptor expression is 
restricted to mucosal surfaces, and P. aeruginosa thrives in the lumen of the airway, perhaps 
the bacteria have evolved mechanisms to take advantage of IFN-λ anti-viral host responses. 
Recently, Hendricks et al. demonstrated that viral infection of CFBE cells promotes the 
apical release of iron, which enhances P. aeruginosa biofilm growth [229]. Future studies, 
investigating how IFN-λ signaling in the CF the lung mucosa promotes an environment that 
is favorable to P. aeruginosa growth could potentially uncover new therapeutic targets that 
reduce bacterial burden.  
While inflammation following a pathogenic insult is essential for host defense, 
excessive or inflammatory responses can cause tissue damage. A multitude of studies have 
demonstrated that endogenous SPMs orchestrate the resolution of inflammatory responses 
and promote the return to tissue homeostasis [152, 186]. However, utilizing SPMs to treat 
infectious disease is only recently becoming an area of active research interest for the 
treatment of pathogen-associated inflammation [173, 251, 252]. Given the limited treatment 
options for RSV, which causes robust and damaging pulmonary inflammation, in the current 
study we investigated if 15-epi LXA4 could be used to treat this respiratory virus infection. 
We found that treatment with 15-epi LXA4 during ongoing RSV infection significantly 
reduced IFN-λ secretion and attenuated viral burden. Interestingly, SPM treatment only had 
an effect if administered 24 or 48 hours post-infection. Thus, our data implies that 15-epi 
LXA4 can only exert its pro-resolving signal when the AECs are responding to viral 
infection. Perhaps, AECs only initiate inflammatory programs that generate 15-epi LXA4 
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signaling targets once a viral replication or PAMP accumulation has reached a threshold. Our 
study indicates that 15-epi LXA4 treatment could be administered days into a viral infection, 
which would be a improvement over traditional anti-viral therapies which need to be 
employed at the early stages of infection to be effective.  
Our study also demonstrated that 15-epi LXA4 administration lessened IFN-λ 
associated P. aeruginosa biofilm growth. Although the effect on bacterial burden is small, 
our study suggests that mucosal SPM treatment could reduce IFN-λ responses that enhance 
secondary bacterial superinfection. The administration of SPMs may provide a novel way to 
target polymicrobial infections rather than using the current standard of cares that target one 
microorganism at a time. Additional work is needed to both titrate the optimal dose of 15-epi 
LXA4, well as determine if other SPMs can be used to treat viral-bacterial co-infections. 
Furthermore, more studies are needed to identify the inflammatory pathways that 15-epi 
LXA4 administration targets in AECs and other cells in the mucosa. Lastly, determining 
other intracellular pathogens that can be curbed by utilizing SPM treatment will be important 
area of future investigation.  
In conclusion, our study supports use of SPM administration in the airway mucosa, 
which could provide a new avenue for therapeutic intervention that may alleviate both 
pathogen burden and detrimental host inflammatory responses.  
 
  
 83 
5.0 OVERALL CONCLUSION AND FUTURE DIRECTIONS 
Our studies demonstrate that not only does P. aeruginosa thrive in an inflammatory 
environment, but also actively promotes persistent inflammation in the CF lung.  In our first 
study we determined that the epoxide hydrolase activity of the P. aeruginosa virulence factor 
Cif, mediated the hydrolysis of epithelial-derived 14,15-EET. The manipulation of AEC 
derived 14,15-EET reduced neutrophil generation of 15-epi LXA4. We further showed that 
the presence of Cif in the BAL fluid of CF patients correlated with elevated inflammatory 
markers and pulmonary function. Cif is the first bacterial epoxide hydrolase that has been 
shown to promote inflammatory pathways. Interestingly, unlike other virulence factors 
expressed by P. aeruginosa, Cif expression is not reduced over time in the CF lung, 
indicating that its function is important for chronic infection. Other bacterial and fungal 
pathogens have been shown to also target host lipid pathways, however in the opposite 
manner [184, 209, 210]. These microorganisms mainly promote the production of pro-
resolving lipid pathways, presumably to conceal themselves from the immune response. Our 
study reveals that P. aeruginosa takes a different approach in the CF lung, instead 
manipulating host lipid signals to promote continual inflammation. While our studies have 
focused on the CF airway, it is important to recognize that Cif may also skew inflammatory 
activities in other pulmonary diseases where patients are commonly infected with P. 
aeruginosa such as ventilator associated pneumonia and COPD. Furthermore, the P. 
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aeruginosa strain PA14, which highly expresses Cif was originally isolated from a burn 
patient. Thus, it is quite possible that P. aeruginosa utilizes this virulence mechanism to 
promote an inflammatory environment in other areas of the body, such as the skin. Future 
studies that determine Cif expression in P. aeruginosa isolates obtained from various host 
etiologies will be important for designing therapeutics and could also provide important clues 
for Cif expression regulation in the host.  
Although it may seem counter productive for a bacterial pathogen to actively induce 
more inflammation, there are a few possible reasons that P. aeruginosa finds vigorous 
inflammation in the CF an accommodating niche. Perhaps, by inciting robust inflammation 
P. aeruginosa outcompetes other more susceptible microorganisms, thereby becoming the 
dominant microorganism in the lung [253]. Inflammation might also provide the bacteria 
with a steady supply of essential nutrients, as our studies demonstrate viral infection 
enhanced the secretion of apical iron by AECs [229].  It is also possible that by removing 
counter regulatory signaling and promoting continual inflammation, the accumulation of 
frustrated and necrotic neutrophils provides the bacteria with more host material to 
incorporate into bacterial biofilms [51, 53, 113]. Lastly, pulmonary inflammation promotes 
the secretion of mucus, which could provide the bacteria more surface area to grow biofilms 
[254, 255]. Although one can only postulate what the exact beneficial mechanism that 
continuous inflammation provides P. aeruginosa, it is clear that the bacteria can survive and 
adapt to the inflammatory CF lung. It is important to note that in immunocompetent hosts 
neutrophil responses are key in regulating P. aeruginosa infections, therefore in the CF lung, 
it is clear that neutrophil dysfunction along with poor mucocillary clearance are key elements 
that allow chronic colonization to occur. 
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During my studies I have gained an appreciation for the enormous contribution of 
epithelial cells in host defense. The production of antimicrobials, regulation of pH, and 
mucociliary clearance are all vital epithelial functions that maintain mucosal homeostasis. 
Although traditionally immunologists consider the epithelium to only afford barrier 
protection, I think of them to be specialized immune cell coordinators, as they orchestrate 
many immune responses at the mucosa. In our study, we show that 14,15-EET secreted from 
the AECs provide a key counter regulatory signal to neutrophils. Moreover, there is a large 
body of literature that show AECs secrete a variety of chemotactic proteins and lipids that 
help coordinate the traffic of granulocytes, lymphocytes and monocytes [7]. As epithelial 
cells are major constituent of many mucosal tissues, future therapies that target this cell type 
could potentially yield new anti-inflammatory therapies.  However, much work remains to be 
done on cellular communication networks at the mucosa, particularly in terms of the 
resolution of inflammation.  
 There is substantial evidence that demonstrates SPMs can be useful for allergic or 
sterile inflammation. Recent studies are also beginning to show the utility SPM treatment for 
alleviating infectious inflammation [167, 245, 256]. Here we show that 15-epi LXA4 
administration to AECs reduces RSV burden and IFN-λ secretion. Although the effect we see 
in our study is small, changing the dose and timing of administration may increase the 
antimicrobial effect of 15-epi LXA4. This investigation revealed that inflammatory pathways 
must be activated prior to 15-epi LXA4 treatment to see an antimicrobial effect. This 
observation is exciting as SPMs treatment may be most effective when administered days 
into a viral infection which could be valuable given that traditional anti-viral therapies 
generally need to be dispensed during early stages of infection to be effective. Further 
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research on supplementing standard of care therapies with SPM treatment for antiviral 
therapy could be very beneficial, especially for chronic viral infections. Novel SPM 
analogues are in development, which have a longer half-life than their endogenous 
counterparts. Perhaps using a 15-epi LXA analogue on virally infected AECs in our model 
may enhance antimicrobial effects. In the future, studies that use SPM treatment may provide 
better patient outcomes during viral infections.  
Future therapies that target the robust inflammatory response in the CF airway are on 
the horizon. Multiple drugs that enhance pro-resolving pathways including CTX-4430 and 
Resunab are currently undergoing clinical trials in CF patients. CTX-4430 is a selective 
inhibitor of leukotriene A4 hydrolase that blocks the production of leukotriene B4, a 
molecule that leads to inflammation and is known to be elevated in CF. Resunab is a first in 
class, synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 
receptor expressed on activated immune cells [257]. CB2 activation triggers endogenous 
pathways that resolve inflammation and halt fibrosis. As the body of literature regarding 
SPM pro-resolving functions in the lung increases, it is likely that their use a therapeutic 
treatment for CF may be forthcoming in the near future. 
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APPENDIX A  
THE PSEUDOMONAS AERUGINOSA LYPOXGENASE LOXA SUPPORTS 
BIOFILM GROWTH ON HUMAN AIRWAY EPITHELIAL CELLS 
This appendix is adapted from:  
Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas 
aeruginosa 15-Lipoxygenase 
Joshua D. Deschamps1, Abiola F. Ogunsola2, J. Brian Jameson II1, Adam Yasgar3, Becca A. 
Flitter2, Cody J. Freedman1, Jeffrey A. Melvin2, Jason V. M. H. Nguyen1, David J. 
Maloney3, Ajit Jadhav3, Anton Simeonov3, Jennifer M. Bomberger2, and Theodore R. 
Holman1 
1Department of Chemistry and Biochemistry, University of California , Santa Cruz, 
California 95064, United States. 
2Department of Microbiology and Molecular Genetics, University of Pittsburgh , Pittsburgh, 
Pennsylvania 15219, United States. 
3National Center for Advancing Translational Sciences, National Institutes of Health , 9800 
Medical Center Drive, MSC 3370, Bethesda, Maryland 20892, United States 
 
These data are reported in the journal of Biochemistry 2016. 55 (23) p3320-40  
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P. aeruginosa secretes the 15-lipoxygenase LoxA, that has the capacity to convert host 
arachidonic acid (AA) into 15-hydroxyeicosatetraenoic acid (15-HETE) [173, 251, 252]. 
LoxA has similar positional specificity for peroxidation of free fatty acids to that of human 
15- lipoxygenase (15-LOX) [212]. It has been proposed that LoxA modulates host defense 
and by altering the host lipid environment, however, the biologic function in vivo is 
unknown. Here we tested the hypothesis that LoxA enhanced P. aeruginosa biofilm growth 
and thus facilitates chronic colonization in the host.  
Biofilm growth of a LoxA transposon mutant PW3111 was tested in parallel with an 
isogenic laboratory strain PA01. Biofilm formation when grown on abiotic surfaces was 
similar between the two strains, indicating no functional consequence of LoxA on abiotic 
biofilm formation (Appendix figure A). However, when biofilms were grown on human 
AECs, PW3111 produced significantly less biofilm compared to PA01 (Appendix figure B). 
Furthermore, the direct addition of recombinant LoxA protein to PW311 or PA01 enhanced 
biofilm formation on AECs (Appendix figure C). These data suggest that LoxA positively 
correlates with P. aeruginosa biofilm production when associated with host epithelial cells.  
AEC expression of 15-LOX is implicated in chronic lung inflammatory diseases such 
as asthma [176]. Type II inflammatory cytokines, IL-4 and IL-13 upregulate the expression 
of 15-LOX in epithelial cells [254, 255, 258]. Furthermore, the production of 15-HETE by 
15-LOX in airway epithelial cells is associated with heightened mucus secretion [254, 255]. 
It is possible that the LoxA enhances epithelial cell mucus secretion allowing for more 
surface area for P. aeruginosa to attach and form biofilms. Future experiments examining the 
role of LoxA in pulmonary inflammation may provide further understanding of how P. 
aeruginosa manipulates the host inflammatory pathways to its own benefit. 
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Appendix Figure 1. (A) PA01 or the LoxA transposon mutant PW3111 we grown on a abiotic surface in Luria 
broth (LB) or minimal essential media (MM) for 24 hours and biofilm mass was quantified by crystal violet. (B) 
PA01 or PW3111 were grown on 16HBE airway epithelial cells for 6 hours and biofilm mass was quantified by 
CFU/ml. Paired T-test; N=4; Mean ±SD (C) PA01 or PW3111 biotic biofilms were quantified following the 
addition of 1µg of recombinant LoxA protein at the time of inoculation N=2; Mean ±SD.  (D) Summary model 
figure. 
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LIST OF ABBREVIATIONS 
14,15-EET  14,15 epoxyeicosatrienoic acid 
 
15-epi LXA4  15-epi lipoxin A4  
AA  Arachidonic acid  
AEC  Airway epithelial cells  
ASL  Airway surface liquid  
BALF  Bronchoalveolar lavage fluid  
CF  Cystic fibrosis  
CFTR  Cystic fibrosis transmembrane conductance regulator  
CFBE  CF bronchial epithelial cell line CFBE41o−  
CF HBE  Primary human CF bronchial epithelial cells  
Cif  CFTR inhibitory factor  
Cif-WT  Cif protein  
Cif-D129S  Cif-D129S mutant  
COX  Cyclooxygenases  
EETs Epoxyeicosatrienoic acids  
IFN α/β  Type I interferon  
IFN-λ  Type III interferon  
LXA4  Lipoxin A4  
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LOX  Lipoxygenases  
SPM Specialized pro-resolving lipid mediator  
RSV  Respiratory syncytial virus  
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